[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Inovo, Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":136},{"warningLetters":4,"total":135},[5,32,54,73,94,116],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":27,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":19,"reference_number":19,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},1667,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-01-02T14:20:00Z\">01\u002F02\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-12-15T05:00:00Z\">12\u002F15\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finopak-ltd-667411-12152023\">Inopak, Ltd.\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations I","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Lester Sampath\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Inopak, Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>24 Executive Pkwy\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ringwood\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07456\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:lester@inopak.com\"> lester@inopak.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 667411\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>December 15, 2023\u003Cbr>\n\u003Cbr>\nDear Mr. Sampath:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Inopak, Ltd., FEI # 1000122232, at 24 Executive Pkwy., Ringwood, New Jersey, from July 24 to August 3, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your August 24, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and 211.22(d)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm utilizes a contract manufacturing organization (CMO) to manufacture your over-the-counter (OTC) drug products such as SaniGuard SF foam hand sanitizer alcohol 70%. Your quality agreement with your CMO stipulates that you are responsible for reviewing documentation including, but not limited to, formulations, specifications, laboratory results, executed “batch records,” and certificates of analysis (COAs). Your quality unit (QU) failed to adequately review these records to ensure required testing was conducted for methanol\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>, before acceptance of components for use in drug manufacture. Additionally, you did not ensure that your ethanol had acceptable levels of known impurities such as benzene, acetaldehyde, and acetal.\u003C\u002Fp>\n\n\u003Cp>You also failed to adequately investigate the leaking drug product received from your CMO. You segregated and labeled the product as rejected as established in your procedures. However, your procedures do not adequately establish a requirement to investigate or communicate to your CMO to investigate non-conformances such as leaking drug products.\u003C\u002Fp>\n\n\u003Cp>Your response states that you will use a sampling plan to review representative records for your drug products manufactured by your CMO. You state that prior to approving release, you will review each formulation and specification to verify acceptable ranges on the COAs and test results and review each lot’s COA, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” shipping results, and inspection results. You state that you will revise your standard operating procedures (SOPs) to reflect your current operations as a private label distributor of drug products. You also state that all finished drug products damaged in shipping has been destroyed and removed.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because your proposed sampling commitment does not conform with your established procedures and quality agreement with your CMO. Your quality agreement appears to contain ambiguities of responsibilities with your CMO that should be addressed to reflect your current operations as stated in your response. Regardless of your established quality agreement as the owner of your drug products, you are ultimately responsible for the quality of your drug products. You also did not provide an investigation for the leaking drug product or communication to your CMO to conduct an investigation. You provided no documentation supporting the claimed destruction of the leaking drug product.\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality system is inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; &nbsp;o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each lot and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003Cbr>\n\u003Cbr>\n• Your investigation and communication to your CMO to investigate non-conforming product received from your CMO and supporting documentation of the destruction of the leaking drug product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to maintain an ongoing stability testing program to support the labeled expiry on your distributed drug products. You utilize a contract testing laboratory to manage your stability testing program and discontinued your ongoing stability program with your contract testing laboratory on January 6, 2023. However, the last lot of drug product manufactured at your facility is labeled with expiration dates through July 29, 2024. There is no assurance that your drug products will remain acceptable throughout their labeled expiry period without an ongoing stability program.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• Your plan for continuing stability studies for your drug products through expiry, including detailed timelines. This plan should also include an assessment of the stability of drug product currently on the U.S. market.\u003Cbr>\n• Your action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including potential customer notifications and recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Use of Contract Manufacturers\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of your drugs regardless of agreements in place with your contract facility. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to cease production of all drugs at this facility.\u003C\u002Fp>\n\n\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective action and preventive action (CAPA).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003Cbr>\n\u003Cbr>\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to orapharm1_responses@fda.hhs.gov. Your written notification should refer to the Warning Letter, CMS # 667411 and reference: FEI 1000122232.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, contact Compliance Officer CAPT Liatte Closs at Liatte.Closs@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Craig Swanson\u003Cbr>\nDeputy Program Division Director\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nOPQO Division I\u003C\u002Fp>\n\n\u003Cp>_______________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>See 21 CFR 211.84; The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol\u003C\u002Fem> at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Lester Sampath\n\nRecipient Title\n\nChief Executive Officer\n\nInopak, Ltd.\n\n24 Executive Pkwy\n\nRingwood, NJ 07456\n\nUnited States\n\nlester@inopak.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nCMS # 667411\n\nDecember 15, 2023\n\nDear Mr. Sampath:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Inopak, Ltd., FEI # 1000122232, at 24 Executive Pkwy., Ringwood, New Jersey, from July 24 to August 3, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your August 24, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and 211.22(d)).\n\nYour firm utilizes a contract manufacturing organization (CMO) to manufacture your over-the-counter (OTC) drug products such as SaniGuard SF foam hand sanitizer alcohol 70%. Your quality agreement with your CMO stipulates that you are responsible for reviewing documentation including, but not limited to, formulations, specifications, laboratory results, executed “batch records,” and certificates of analysis (COAs). Your quality unit (QU) failed to adequately review these records to ensure required testing was conducted for methanol1, before acceptance of components for use in drug manufacture. Additionally, you did not ensure that your ethanol had acceptable levels of known impurities such as benzene, acetaldehyde, and acetal.\n\nYou also failed to adequately investigate the leaking drug product received from your CMO. You segregated and labeled the product as rejected as established in your procedures. However, your procedures do not adequately establish a requirement to investigate or communicate to your CMO to investigate non-conformances such as leaking drug products.\n\nYour response states that you will use a sampling plan to review representative records for your drug products manufactured by your CMO. You state that prior to approving release, you will review each formulation and specification to verify acceptable ranges on the COAs and test results and review each lot’s COA, “(b)(4),” shipping results, and inspection results. You state that you will revise your standard operating procedures (SOPs) to reflect your current operations as a private label distributor of drug products. You also state that all finished drug products damaged in shipping has been destroyed and removed.\n\nYour response is inadequate because your proposed sampling commitment does not conform with your established procedures and quality agreement with your CMO. Your quality agreement appears to contain ambiguities of responsibilities with your CMO that should be addressed to reflect your current operations as stated in your response. Regardless of your established quality agreement as the owner of your drug products, you are ultimately responsible for the quality of your drug products. You also did not provide an investigation for the leaking drug product or communication to your CMO to conduct an investigation. You provided no documentation supporting the claimed destruction of the leaking drug product.\n\nYour firm’s quality system is inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each lot and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\n• Your investigation and communication to your CMO to investigate non-conforming product received from your CMO and supporting documentation of the destruction of the leaking drug product.\n\n2. Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a)).\n\nYou failed to maintain an ongoing stability testing program to support the labeled expiry on your distributed drug products. You utilize a contract testing laboratory to manage your stability testing program and discontinued your ongoing stability program with your contract testing laboratory on January 6, 2023. However, the last lot of drug product manufactured at your facility is labeled with expiration dates through July 29, 2024. There is no assurance that your drug products will remain acceptable throughout their labeled expiry period without an ongoing stability program.\n\nIn response to this letter, provide:\n\n• Your plan for continuing stability studies for your drug products through expiry, including detailed timelines. This plan should also include an assessment of the stability of drug product currently on the U.S. market.\n\n• Your action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including potential customer notifications and recalls.\n\nUse of Contract Manufacturers\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of your drugs regardless of agreements in place with your contract facility. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\n\nDrug Production Ceased\n\nWe acknowledge your commitment to cease production of all drugs at this facility.\n\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective action and preventive action (CAPA).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to orapharm1_responses@fda.hhs.gov. Your written notification should refer to the Warning Letter, CMS # 667411 and reference: FEI 1000122232.\n\nIf you have any questions, contact Compliance Officer CAPT Liatte Closs at Liatte.Closs@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCraig Swanson\n\nDeputy Program Division Director\n\nU.S. Food and Drug Administration\n\nOPQO Division I\n\n_______________\n\n1 See 21 CFR 211.84; The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.","Inopak, Ltd.","inopak-ltd-667411-12152023","2026-08-18T06:42:28.994808+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finopak-ltd-667411-12152023","2026-10-26T08:08:59.210973+00:00","Warning Letter","Issued","2024-01-02","667411","Drugs","Division of Pharmaceutical Quality Operations I","Mr. Lester Sampath","2026-08-20T00:23:54.293+00:00","VIA Electronic Mail","2023-12-15",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":26,"closeout_date":19,"issuing_office":38,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":52,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},280,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2026-03-10T04:00:00Z\">03\u002F10\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-05T05:00:00Z\">03\u002F05\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnovo-nordisk-inc-717576-03052026\">Novo Nordisk Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Postmarketing Adverse Drug Experience Reporting Requirements","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>26-HFD-45-03-01\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. David S. Moore\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Novo Nordisk Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>800 Scudders Mill Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Plainsboro\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08536\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>&nbsp;\u003C\u002Fp>\u003Cp>Mr. David S. Moore FDA Ref. No.: 26-HFD-45-03-01\u003Cbr>President\u003Cbr>Novo Nordisk Inc.\u003Cbr>800 Scudders Mill Road\u003Cbr>Plainsboro, New Jersey 08536\u003C\u002Fp>\u003Cp>Dear Mr. Moore:\u003C\u002Fp>\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at your firm, Novo Nordisk Inc. (hereinafter referred to as NNI), between January 13 and February 7, 2025. The investigators representing FDA reviewed your compliance with postmarketing adverse drug experience (PADE) regulations. The inspection revealed serious violations of PADE reporting requirements found in section 505(k) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. 355(k)] and Title 21, Code of Federal Regulations (21 CFR) 314.80. Failure to comply with section 505(k) is a prohibited act under section 301(e) of the FD&amp;C Act [21 U.S.C. 331(e)].\u003C\u002Fp>\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to ensure that accurate, reliable, and timely safety data are submitted to FDA for the monitoring of product safety, and to ensure compliance with PADE regulations.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the investigators presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your written response to the Form FDA 483 dated March 3, 2025, and your subsequent correspondence dated April 11, 2025; May 2, 2025; June 6, 2025; July 11, 2025; September 19, 2025; October 31, 2025; and January 15, 2026.\u003C\u002Fp>\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response and correspondence dated March 3, 2025; April 11, 2025; May 2, 2025; June 6, 2025; July 11, 2025; September 19, 2025; October 31, 2025; and January 15, 2026, it appears that you did not adhere to the applicable statutory requirements in the FD&amp;C Act and applicable regulations contained in 21 CFR part 314.\u003C\u002Fp>\u003Cp>We wish to emphasize the following:\u003C\u002Fp>\u003Cp>Failure to develop written procedures for the surveillance, receipt, evaluation, and reporting of postmarketing adverse drug experiences (ADEs) to FDA as required by 21 CFR 314.80(b).\u003C\u002Fp>\u003Cp>As an application holder of products with active ingredients including semaglutide, liraglutide, nedosiran sodium, and estradiol, NNI is required to develop written procedures for the surveillance, receipt, evaluation, and reporting of postmarketing adverse drug experiences (ADEs) to FDA. You developed written procedures that failed to ensure that you, and your contractor acting on your behalf, complied with all applicable PADE regulations for the surveillance, receipt, evaluation, and reporting of ADEs.\u003C\u002Fp>\u003Cp>Examples of this failure include but are not limited to the following:\u003C\u002Fp>\u003Cp>1. You failed to develop written procedures, as required under 21 CFR 314.80(b), that ensured that you, and your contractor acting on your behalf, reported all serious and unexpected ADEs to FDA within 15 calendar days, in accordance with 21 CFR 314.80(c)(1)(i). PADE regulations require the applicant to report each ADE that is both serious and unexpected, whether foreign or domestic, no later than 15 calendar days from the initial receipt of the information by the applicant (21 CFR 314.80(c)(1)(i)). Specifically:\u003C\u002Fp>\u003Cp>a. Your written procedure Q014048, “Handling of Adverse Events and Other Safety Information” (Ver: 28.0, Effective Date: 03 Oct 2024), allowed ADEs reported to NNI to be rejected or cancelled (and therefore not to be reported to FDA) if the ADE was considered by the reporter to be unrelated to the product. Specifically, Q014048 excludes reports from the definition of “adverse reaction” if “the reporters specifically state that they believe the events to be unrelated or that a causal relationship can be excluded.” This definition is inconsistent with FDA regulations, which define an ADE as “[a]ny adverse event associated with the use of a drug in humans, whether or not considered drug-related.” FDA’s regulations require applicants to develop written procedures for, among other things, the reporting of ADEs regardless of whether the event is considered causally related to the product. An ADE that is determined to be both serious and unexpected must be reported to FDA no later than 15 days from the date of initial receipt. Based on your written procedure, your staff or contractor cancelled or rejected serious and unexpected ADEs that were required to be reported within 15 calendar days because they documented these events as being unrelated to the product. For example, Argus\u003Ca id=\"footnoteref1_pddfmla\" href=\"#footnote1_pddfmla\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp;Case #1331385 involves a consumer who was disabled after experiencing a stroke, which is a serious and unexpected ADE, while receiving liraglutide. The consumer reported that the stroke was not related to liraglutide; therefore, you rejected this case. As a result, you failed to report serious and unexpected ADEs to FDA within 15 calendar days, as required by PADE regulations.\u003C\u002Fp>\u003Cp>During the inspection, you stated that you opened deviation DV0166369 in April 2024 after discovering that not all reportable serious and unexpected ADEs were submitted to FDA because the ADEs were cancelled or rejected by your staff or contractor and were documented as being “incidental” or “incidental and unrelated.” You identified your written procedures, including Q014048 (both the current and prior versions), as a root cause for this deviation, because both the current and prior versions allowed ADEs reported to NNI to be rejected or cancelled based on the reporter’s assessment of a lack of causality of the event to the product. The root-cause analysis noted that while the exclusion of certain ADEs from reporting as described in the written procedures was consistent with foreign regulatory authority regulations, it was not consistent with U.S. regulations. Although you closed deviation DV0166369 in December 2024, you did not ensure that your corrective and preventive actions were effectively implemented to resolve the existing issues and to prevent recurrence of the noncompliance. Specifically, while you ensured that prior versions of Q014048 were no longer in use, you did not update the definition of “adverse reactions” to remove references to relatedness and causality in the current version of Q014048. Additionally, you closed deviation DV0166369 without confirming the completion of your corrective action to submit all reportable serious and unexpected ADEs to FDA. Although you stated in your written response that you submitted these ADEs to FDA after the investigators discussed them with you during this inspection, you did not provide the case numbers and dates submitted to FDA for all cases with serious and unexpected ADEs that were identified as part of deviation DV0166369. As a result, FDA cannot verify that all serious and unexpected ADEs identified in this deviation were submitted to FDA. Furthermore, you did not provide sufficient information regarding how you will implement the corrective and preventive actions identified in this deviation to ensure that all serious and unexpected ADEs are reported to FDA.\u003C\u002Fp>\u003Cp>In your written response dated March 3, 2025, and in subsequent correspondence, you described corrective actions including but not limited to: (1) revising procedures and other documents to remove certain terminology that created ambiguity and led to serious and unexpected ADEs not being reported to FDA; (2) updating definitions and documentation of the term “spontaneous cases”; and (3) performing a retrospective review of cases to ensure that all valid cases were submitted to FDA. Further, you stated that all cases that were identified as 15-day Alert reports as part of deviation DV0166369 had been submitted to FDA as of February 6, 2025.\u003C\u002Fp>\u003Cp>While we acknowledge the corrective and preventive actions you have taken or plan to take, your written response and subsequent correspondence are inadequate because you did not provide sufficient details for the Agency to determine whether your actions effectively resolved the existing issues and will prevent similar violations in the future. Specifically, you did not provide sufficient details about how your updated procedures, guidance, and training materials will ensure future compliance with reporting serious and unexpected ADEs to FDA in a timely manner.\u003C\u002Fp>\u003Cp>b. Your written procedure Q014048, “Handling of Adverse Events and Other Safety Information” (Ver: 28.0, Effective Date: 03 Oct 2024), states that the minimum criteria for Individual Case Safety Reports (ICSRs) to qualify for submission in an expedited manner are: (1) one or more identifiable reporters; (2) a single identifiable patient; (3) a suspected NNI product; and (4) a suspected adverse reaction. However, your written procedure did not ensure that you, and the call-center contractors acting on your behalf, correctly received, reviewed, and processed ADE information, which resulted in the failure to submit serious and unexpected ADEs that were required to be reported to FDA within 15 calendar days.\u003C\u002Fp>\u003Cp>Specifically, you and your contractors inappropriately invalidated 15-day Alert reports because of a lack of patient identifiers; however, during the inspection, FDA identified valid patient identifiers in source documents for these reports. These reports were not submitted to FDA until they were discussed with you during the inspection. For example, Argus Case #1342548 includes a consumer reporting a death for a male patient who received semaglutide; however, you invalidated the case because you failed to capture the patient identifier. During the inspection, FDA found the patient identifier in the source documents for this case. As a result of this erroneous invalidation, you failed to report serious and unexpected ADEs to FDA within 15 calendar days, as required.\u003C\u002Fp>\u003Cp>We note that you identified this issue when \u003Cstrong>(b)(4)\u003C\u002Fstrong> served as your call-center contractor between May 12 and October 12, 2023. You later terminated your contract with \u003Cstrong>(b)(4)\u003C\u002Fstrong> ⁽ᵇ⁾ ⁽⁴⁾ and switched your call-center contractor to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, starting on October 13, 2023. You also opened deviation DV0155511 in December 2023 in response to issues observed with \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Although you switched your call-center contractor to \u003Cstrong>(b)(4)\u003C\u002Fstrong> and completed corrective and preventive actions as part of deviation DV0155511, you continued to invalidate cases of ADEs for lack of a patient identifier, despite the patient identifiers’ being available in accordance with written procedure Q014048 and the cases’ otherwise qualifying as reportable. Therefore, you did not ensure that your corrective and preventive actions (for example, review and creation of training resources and content for vendors) were effectively implemented to resolve the existing issues and to prevent recurrence of the noncompliance.\u003C\u002Fp>\u003Cp>In your March 3, 2025, written response and in subsequent correspondence, you stated proposed corrective actions, including but not limited to: (1) conducting retrospective reviews of cases to ensure that all valid cases were submitted to FDA; (2) drafting work instructions related to ICSR quality checks and verification, including source data verification; (3) planning a phased approach to transition safety case intake from the contracted call-center agents to dedicated insourced patient safety agents, who are health care professionals; (4) performing an assessment of the vendor management program; and (5) creating a Vendor Management team, a Vendor Quality team, and a Training team dedicated to your U.S. Patient Safety team, to ensure adequate vendor training and oversight.\u003C\u002Fp>\u003Cp>While we acknowledge the corrective and preventive actions you have taken or plan to take, your written response is inadequate because you did not provide information about whether your proposed actions will prevent similar violations in the future. For example, you did not provide specific information about how you will ensure that vendors acting on your behalf correctly receive, review, and process ADE information, including how you will maintain oversight related to delegated functions. Specifically, you did not provide sufficient details about how your Vendor Management, Quality, and Training teams will operate, what their activities will be, or how these teams will ensure that contractors acting on your behalf will accurately and completely capture ADEs, perform quality check activities, and comply with all applicable PADE requirements. In addition, you did not describe how the “insourced” call center will operate, nor did you provide adequate information to ensure that your insourced call center will comply with PADE requirements in the future.\u003C\u002Fp>\u003Cp>c. Your written procedure Q040018, “Handling Individual Safety Cases in the Global Safety Database” (Ver 43.0, Effective Date: 17 May 2024), states that most serious adverse reactions should enter medical review by calendar day 9 following the awareness date, and they should complete medical review by calendar day 10 following the awareness date. However, your written procedure failed to ensure that cases completed “medical review” within the timelines specified in your written procedure. Rather, cases remained in “medical review” status longer than specified in your written procedure, resulting in your failure to submit 15-day Alert reports to FDA within the required time frame. During the inspection, FDA identified and made you aware of serious and unexpected ADEs that were not submitted to FDA because they remained in “medical review” status beyond the timeline specified in your written procedures. For example, in Argus Case #1334278, you received information on December 9, 2024, from a consumer who reported suicidal ideation while taking semaglutide. This case entered “medical review” status on December 16, 2024; however, medical review was not performed until February 3, 2025, after being identified during FDA’s inspection, and the case was submitted to FDA on February 5, 2025. As a result, you failed to report serious and unexpected ADEs to FDA within 15 calendar days, as required by PADE regulations.\u003C\u002Fp>\u003Cp>In your March 3, 2025, written response and your April 11, 2025, correspondence, you stated that your corrective actions included but were not limited to a requirement for daily review of patient safety cases across each workflow state. However, your written response is inadequate because you did not provide any information about whether your proposed actions will prevent similar violations in the future. For example, you did not provide sufficient details regarding the root cause of this violation, including why these cases remained in “medical review” status beyond the time frames specified in your written procedure. You also have not provided an assessment of whether, and to what extent, this issue implicates the timely reporting of other cases in your product portfolio.\u003C\u002Fp>\u003Cp>2. You failed to develop written procedures that ensured all ADEs that are the subject of 15-day Alert reports were promptly investigated in accordance with 21 CFR 314.80(c)(1)(ii). PADE regulations require that the applicant must promptly investigate all ADEs that are the subject of postmarketing 15-day Alert reports (21 CFR 314.80(c)(1)(ii)).\u003C\u002Fp>\u003Cp>Your written procedure Q0360683, “Case Management Workflow at Novo Nordisk Inc. Patient Safety” (Ver: 7.0, Approved Date: 04 Nov 2024), stated that you did not require follow-up on reported ADEs if consent was not obtained from the reporter and if the reporter was a non-health care professional. Based on this written procedure, you, and your contractor acting on your behalf, failed to promptly investigate ADEs that were subject to 15-day Alert reporting because you did not follow up with reporters to request additional information unless you explicitly obtained consent from the reporter. PADE regulations do not require the obtaining of consent to acquire additional information. As a result, you failed to investigate serious and unexpected ADEs as required by PADE regulations.\u003C\u002Fp>\u003Cp>For example, Argus Case #1171264 includes a non-health care professional reporting the death of a patient receiving semaglutide; however, you failed to promptly investigate because consent was not obtained from the reporter and the reporter was a non-health care professional, as stated in your written procedure. This case was closed without your reporting it to FDA.\u003C\u002Fp>\u003Cp>Procedure Q0360683 also required that NNI perform two follow-up attempts for serious cases in which a death is reported, to obtain relevant safety information for reporting to FDA. However, you failed to promptly investigate Argus Case #1079792, in which a physician reported to your company representative that a patient taking semaglutide was depressed and committed suicide. You failed to document any attempt to obtain additional information from the reporter, including patient identifiers. As of the date of issuance of this letter, this case has not been submitted to FDA.\u003C\u002Fp>\u003Cp>In your written response dated March 3, 2025, you attributed the failure to promptly investigate serious and unexpected ADEs to a procedural gap that required unnecessary consent from the reporter. In your written response and in subsequent correspondence, you described corrective actions including but not limited to: (1) revising local and global SOPs and trainings to remove the requirement to obtain consent from reporters for follow-up; (2) removing fields requiring reporters’ consent from local IT platforms; (3) sending a communication to all vendors and revising safety data exchange agreement (SDEA) templates to clarify that consent is not a predicate requirement to collecting information from a reporter; and (4) conducting a retrospective review of cases to assess that appropriately timed and documented follow-up attempts with reporters were conducted. However, your written response is inadequate because you did not provide information about how your proposed or completed corrective actions would prevent similar violations in the future. For example, you did not provide sufficient details about your quality-control activities, including how you will maintain oversight of vendors with whom you contract to fulfill any of your ADE responsibilities.\u003C\u002Fp>\u003Cp>Additionally, your written response did not specifically address how you will conduct appropriate follow-up, as required by 21 CFR 314.80(c)(1)(ii), for 15-day Alert reports that were not submitted at the time of the inspection.\u003C\u002Fp>\u003Cp>In your March 3, 2025, written response, and in subsequent correspondence, you described corrective actions including but not limited to your engagement with a consultant to perform reviews of your pharmacovigilance processes and associated interfaces, as well as your deviation system and your corrective and preventive action system, to ensure that all cases have been reported to FDA and all deviations have been handled adequately. You also stated that your consultant is engaged in a retrospective review of all closed pharmacovigilance-related deviations dating back to June 2017, and that you have created a deviation review board. We acknowledge that your retrospective review of deviations is complete and that you have received the final report. For each major deviation that may affect compliance with PADE regulations and that has a Quality Assurance approval date after 01 Jan 2021, including those listed on the Deviations Handling request provided to the investigators during the inspection, you should submit a description of the deviation, date of identification, current status, the root-cause analysis, an assessment of the impact, the status of all corrective and preventive actions, and the timeline and results for effectiveness checks.\u003C\u002Fp>\u003Cp>While we acknowledge the corrective and preventive actions your firm has taken since our inspection, your response is inadequate because you did not provide sufficient details to determine whether your actions will effectively prevent similar violations in the future. Your explanations, when taken into consideration with the violations described above and your failure to adequately address your noncompliance, suggest systemic failures with your surveillance, receipt, evaluation, and reporting of ADEs to FDA. In addition, your failure to identify and assess the root cause(s) of deficiencies discussed in this letter raises concerns about your firm’s ability to monitor the safety of your products, including through oversight of vendors with whom you contract to fulfill any of your ADE responsibilities. While this inspection focused on NNI’s compliance with PADE regulations for a sample of NNI’s products, including semaglutide, liraglutide, nedosiran sodium, and estradiol, based on the nature of the inspection’s findings and your written response and correspondence, we have serious concerns about the scope and impact of these violations on your entire product portfolio.\u003C\u002Fp>\u003Cp>FDA relies on the complete, accurate, and timely submission of ADEs to monitor a product’s safety profile and uphold FDA’s mission to protect and promote public health. Reporting ADEs to FDA within the required time frames is necessary for the ongoing monitoring of drug safety profiles. Failure to report and investigate ADEs may limit the safety information that FDA may need when monitoring potential safety signals.\u003C\u002Fp>\u003Cp>We emphasize that as an application holder, it is your responsibility to ensure that you comply with all applicable PADE requirements, including when you contract with a vendor to fulfill any of your ADE responsibilities. Your failure to develop procedures that ensure the submission of 15-day Alert reports and the prompt investigation of ADEs that were the subject of 15-day Alert reports raises significant concerns about your ability to accurately and completely report product safety information to the FDA in accordance with PADE requirements.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies that exist at NNI. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that you comply with FDA regulations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b) and allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action. If you believe you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Should you have any questions or concerns regarding this letter or the inspection, please email FDA at CDER-OSI-ADE@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\u003Cp>Dipti Kalra R.Ph., M.S., MBA Branch Chief\u003Cbr>Postmarketing Safety Branch\u003Cbr>Division of Enforcement and Postmarketing Safety Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration Building 51, Room 5343\u003Cbr>10903 New Hampshire Avenue Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>Sincerely,\u003C\u002Fp>\u003Cp>{See appended electronic signature page}\u003C\u002Fp>\u003Cp>David C. Burrow, Pharm.D., J.D. Director\u003Cbr>Office of Scientific Investigations Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>\u002Fs\u002F\u003Cbr>------------------------------------------------------------\u003Cbr>DAVID C BURROW\u003Cbr>03\u002F05\u002F2026 08:24:50 AM\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_pddfmla\">\u003Ca href=\"#footnoteref1_pddfmla\">1\u003C\u002Fa>Argus is NNI’s drug safety database.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nReference #:\n\n26-HFD-45-03-01\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. David S. Moore\n\nRecipient Title\n\nPresident\n\nNovo Nordisk Inc.\n\n800 Scudders Mill Road\n\nPlainsboro, NJ 08536\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\n\nMr. David S. Moore FDA Ref. No.: 26-HFD-45-03-01\nPresident\nNovo Nordisk Inc.\n800 Scudders Mill Road\nPlainsboro, New Jersey 08536\nDear Mr. Moore:\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at your firm, Novo Nordisk Inc. (hereinafter referred to as NNI), between January 13 and February 7, 2025. The investigators representing FDA reviewed your compliance with postmarketing adverse drug experience (PADE) regulations. The inspection revealed serious violations of PADE reporting requirements found in section 505(k) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 355(k)] and Title 21, Code of Federal Regulations (21 CFR) 314.80. Failure to comply with section 505(k) is a prohibited act under section 301(e) of the FD&C Act [21 U.S.C. 331(e)].\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to ensure that accurate, reliable, and timely safety data are submitted to FDA for the monitoring of product safety, and to ensure compliance with PADE regulations.\nAt the conclusion of the inspection, the investigators presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your written response to the Form FDA 483 dated March 3, 2025, and your subsequent correspondence dated April 11, 2025; May 2, 2025; June 6, 2025; July 11, 2025; September 19, 2025; October 31, 2025; and January 15, 2026.\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response and correspondence dated March 3, 2025; April 11, 2025; May 2, 2025; June 6, 2025; July 11, 2025; September 19, 2025; October 31, 2025; and January 15, 2026, it appears that you did not adhere to the applicable statutory requirements in the FD&C Act and applicable regulations contained in 21 CFR part 314.\nWe wish to emphasize the following:\nFailure to develop written procedures for the surveillance, receipt, evaluation, and reporting of postmarketing adverse drug experiences (ADEs) to FDA as required by 21 CFR 314.80(b).\nAs an application holder of products with active ingredients including semaglutide, liraglutide, nedosiran sodium, and estradiol, NNI is required to develop written procedures for the surveillance, receipt, evaluation, and reporting of postmarketing adverse drug experiences (ADEs) to FDA. You developed written procedures that failed to ensure that you, and your contractor acting on your behalf, complied with all applicable PADE regulations for the surveillance, receipt, evaluation, and reporting of ADEs.\nExamples of this failure include but are not limited to the following:\n1. You failed to develop written procedures, as required under 21 CFR 314.80(b), that ensured that you, and your contractor acting on your behalf, reported all serious and unexpected ADEs to FDA within 15 calendar days, in accordance with 21 CFR 314.80(c)(1)(i). PADE regulations require the applicant to report each ADE that is both serious and unexpected, whether foreign or domestic, no later than 15 calendar days from the initial receipt of the information by the applicant (21 CFR 314.80(c)(1)(i)). Specifically:\na. Your written procedure Q014048, “Handling of Adverse Events and Other Safety Information” (Ver: 28.0, Effective Date: 03 Oct 2024), allowed ADEs reported to NNI to be rejected or cancelled (and therefore not to be reported to FDA) if the ADE was considered by the reporter to be unrelated to the product. Specifically, Q014048 excludes reports from the definition of “adverse reaction” if “the reporters specifically state that they believe the events to be unrelated or that a causal relationship can be excluded.” This definition is inconsistent with FDA regulations, which define an ADE as “[a]ny adverse event associated with the use of a drug in humans, whether or not considered drug-related.” FDA’s regulations require applicants to develop written procedures for, among other things, the reporting of ADEs regardless of whether the event is considered causally related to the product. An ADE that is determined to be both serious and unexpected must be reported to FDA no later than 15 days from the date of initial receipt. Based on your written procedure, your staff or contractor cancelled or rejected serious and unexpected ADEs that were required to be reported within 15 calendar days because they documented these events as being unrelated to the product. For example, Argus1 Case #1331385 involves a consumer who was disabled after experiencing a stroke, which is a serious and unexpected ADE, while receiving liraglutide. The consumer reported that the stroke was not related to liraglutide; therefore, you rejected this case. As a result, you failed to report serious and unexpected ADEs to FDA within 15 calendar days, as required by PADE regulations.\nDuring the inspection, you stated that you opened deviation DV0166369 in April 2024 after discovering that not all reportable serious and unexpected ADEs were submitted to FDA because the ADEs were cancelled or rejected by your staff or contractor and were documented as being “incidental” or “incidental and unrelated.” You identified your written procedures, including Q014048 (both the current and prior versions), as a root cause for this deviation, because both the current and prior versions allowed ADEs reported to NNI to be rejected or cancelled based on the reporter’s assessment of a lack of causality of the event to the product. The root-cause analysis noted that while the exclusion of certain ADEs from reporting as described in the written procedures was consistent with foreign regulatory authority regulations, it was not consistent with U.S. regulations. Although you closed deviation DV0166369 in December 2024, you did not ensure that your corrective and preventive actions were effectively implemented to resolve the existing issues and to prevent recurrence of the noncompliance. Specifically, while you ensured that prior versions of Q014048 were no longer in use, you did not update the definition of “adverse reactions” to remove references to relatedness and causality in the current version of Q014048. Additionally, you closed deviation DV0166369 without confirming the completion of your corrective action to submit all reportable serious and unexpected ADEs to FDA. Although you stated in your written response that you submitted these ADEs to FDA after the investigators discussed them with you during this inspection, you did not provide the case numbers and dates submitted to FDA for all cases with serious and unexpected ADEs that were identified as part of deviation DV0166369. As a result, FDA cannot verify that all serious and unexpected ADEs identified in this deviation were submitted to FDA. Furthermore, you did not provide sufficient information regarding how you will implement the corrective and preventive actions identified in this deviation to ensure that all serious and unexpected ADEs are reported to FDA.\nIn your written response dated March 3, 2025, and in subsequent correspondence, you described corrective actions including but not limited to: (1) revising procedures and other documents to remove certain terminology that created ambiguity and led to serious and unexpected ADEs not being reported to FDA; (2) updating definitions and documentation of the term “spontaneous cases”; and (3) performing a retrospective review of cases to ensure that all valid cases were submitted to FDA. Further, you stated that all cases that were identified as 15-day Alert reports as part of deviation DV0166369 had been submitted to FDA as of February 6, 2025.\nWhile we acknowledge the corrective and preventive actions you have taken or plan to take, your written response and subsequent correspondence are inadequate because you did not provide sufficient details for the Agency to determine whether your actions effectively resolved the existing issues and will prevent similar violations in the future. Specifically, you did not provide sufficient details about how your updated procedures, guidance, and training materials will ensure future compliance with reporting serious and unexpected ADEs to FDA in a timely manner.\nb. Your written procedure Q014048, “Handling of Adverse Events and Other Safety Information” (Ver: 28.0, Effective Date: 03 Oct 2024), states that the minimum criteria for Individual Case Safety Reports (ICSRs) to qualify for submission in an expedited manner are: (1) one or more identifiable reporters; (2) a single identifiable patient; (3) a suspected NNI product; and (4) a suspected adverse reaction. However, your written procedure did not ensure that you, and the call-center contractors acting on your behalf, correctly received, reviewed, and processed ADE information, which resulted in the failure to submit serious and unexpected ADEs that were required to be reported to FDA within 15 calendar days.\nSpecifically, you and your contractors inappropriately invalidated 15-day Alert reports because of a lack of patient identifiers; however, during the inspection, FDA identified valid patient identifiers in source documents for these reports. These reports were not submitted to FDA until they were discussed with you during the inspection. For example, Argus Case #1342548 includes a consumer reporting a death for a male patient who received semaglutide; however, you invalidated the case because you failed to capture the patient identifier. During the inspection, FDA found the patient identifier in the source documents for this case. As a result of this erroneous invalidation, you failed to report serious and unexpected ADEs to FDA within 15 calendar days, as required.\nWe note that you identified this issue when (b)(4) served as your call-center contractor between May 12 and October 12, 2023. You later terminated your contract with (b)(4) ⁽ᵇ⁾ ⁽⁴⁾ and switched your call-center contractor to (b)(4), starting on October 13, 2023. You also opened deviation DV0155511 in December 2023 in response to issues observed with (b)(4). Although you switched your call-center contractor to (b)(4) and completed corrective and preventive actions as part of deviation DV0155511, you continued to invalidate cases of ADEs for lack of a patient identifier, despite the patient identifiers’ being available in accordance with written procedure Q014048 and the cases’ otherwise qualifying as reportable. Therefore, you did not ensure that your corrective and preventive actions (for example, review and creation of training resources and content for vendors) were effectively implemented to resolve the existing issues and to prevent recurrence of the noncompliance.\nIn your March 3, 2025, written response and in subsequent correspondence, you stated proposed corrective actions, including but not limited to: (1) conducting retrospective reviews of cases to ensure that all valid cases were submitted to FDA; (2) drafting work instructions related to ICSR quality checks and verification, including source data verification; (3) planning a phased approach to transition safety case intake from the contracted call-center agents to dedicated insourced patient safety agents, who are health care professionals; (4) performing an assessment of the vendor management program; and (5) creating a Vendor Management team, a Vendor Quality team, and a Training team dedicated to your U.S. Patient Safety team, to ensure adequate vendor training and oversight.\nWhile we acknowledge the corrective and preventive actions you have taken or plan to take, your written response is inadequate because you did not provide information about whether your proposed actions will prevent similar violations in the future. For example, you did not provide specific information about how you will ensure that vendors acting on your behalf correctly receive, review, and process ADE information, including how you will maintain oversight related to delegated functions. Specifically, you did not provide sufficient details about how your Vendor Management, Quality, and Training teams will operate, what their activities will be, or how these teams will ensure that contractors acting on your behalf will accurately and completely capture ADEs, perform quality check activities, and comply with all applicable PADE requirements. In addition, you did not describe how the “insourced” call center will operate, nor did you provide adequate information to ensure that your insourced call center will comply with PADE requirements in the future.\nc. Your written procedure Q040018, “Handling Individual Safety Cases in the Global Safety Database” (Ver 43.0, Effective Date: 17 May 2024), states that most serious adverse reactions should enter medical review by calendar day 9 following the awareness date, and they should complete medical review by calendar day 10 following the awareness date. However, your written procedure failed to ensure that cases completed “medical review” within the timelines specified in your written procedure. Rather, cases remained in “medical review” status longer than specified in your written procedure, resulting in your failure to submit 15-day Alert reports to FDA within the required time frame. During the inspection, FDA identified and made you aware of serious and unexpected ADEs that were not submitted to FDA because they remained in “medical review” status beyond the timeline specified in your written procedures. For example, in Argus Case #1334278, you received information on December 9, 2024, from a consumer who reported suicidal ideation while taking semaglutide. This case entered “medical review” status on December 16, 2024; however, medical review was not performed until February 3, 2025, after being identified during FDA’s inspection, and the case was submitted to FDA on February 5, 2025. As a result, you failed to report serious and unexpected ADEs to FDA within 15 calendar days, as required by PADE regulations.\nIn your March 3, 2025, written response and your April 11, 2025, correspondence, you stated that your corrective actions included but were not limited to a requirement for daily review of patient safety cases across each workflow state. However, your written response is inadequate because you did not provide any information about whether your proposed actions will prevent similar violations in the future. For example, you did not provide sufficient details regarding the root cause of this violation, including why these cases remained in “medical review” status beyond the time frames specified in your written procedure. You also have not provided an assessment of whether, and to what extent, this issue implicates the timely reporting of other cases in your product portfolio.\n2. You failed to develop written procedures that ensured all ADEs that are the subject of 15-day Alert reports were promptly investigated in accordance with 21 CFR 314.80(c)(1)(ii). PADE regulations require that the applicant must promptly investigate all ADEs that are the subject of postmarketing 15-day Alert reports (21 CFR 314.80(c)(1)(ii)).\nYour written procedure Q0360683, “Case Management Workflow at Novo Nordisk Inc. Patient Safety” (Ver: 7.0, Approved Date: 04 Nov 2024), stated that you did not require follow-up on reported ADEs if consent was not obtained from the reporter and if the reporter was a non-health care professional. Based on this written procedure, you, and your contractor acting on your behalf, failed to promptly investigate ADEs that were subject to 15-day Alert reporting because you did not follow up with reporters to request additional information unless you explicitly obtained consent from the reporter. PADE regulations do not require the obtaining of consent to acquire additional information. As a result, you failed to investigate serious and unexpected ADEs as required by PADE regulations.\nFor example, Argus Case #1171264 includes a non-health care professional reporting the death of a patient receiving semaglutide; however, you failed to promptly investigate because consent was not obtained from the reporter and the reporter was a non-health care professional, as stated in your written procedure. This case was closed without your reporting it to FDA.\nProcedure Q0360683 also required that NNI perform two follow-up attempts for serious cases in which a death is reported, to obtain relevant safety information for reporting to FDA. However, you failed to promptly investigate Argus Case #1079792, in which a physician reported to your company representative that a patient taking semaglutide was depressed and committed suicide. You failed to document any attempt to obtain additional information from the reporter, including patient identifiers. As of the date of issuance of this letter, this case has not been submitted to FDA.\nIn your written response dated March 3, 2025, you attributed the failure to promptly investigate serious and unexpected ADEs to a procedural gap that required unnecessary consent from the reporter. In your written response and in subsequent correspondence, you described corrective actions including but not limited to: (1) revising local and global SOPs and trainings to remove the requirement to obtain consent from reporters for follow-up; (2) removing fields requiring reporters’ consent from local IT platforms; (3) sending a communication to all vendors and revising safety data exchange agreement (SDEA) templates to clarify that consent is not a predicate requirement to collecting information from a reporter; and (4) conducting a retrospective review of cases to assess that appropriately timed and documented follow-up attempts with reporters were conducted. However, your written response is inadequate because you did not provide information about how your proposed or completed corrective actions would prevent similar violations in the future. For example, you did not provide sufficient details about your quality-control activities, including how you will maintain oversight of vendors with whom you contract to fulfill any of your ADE responsibilities.\nAdditionally, your written response did not specifically address how you will conduct appropriate follow-up, as required by 21 CFR 314.80(c)(1)(ii), for 15-day Alert reports that were not submitted at the time of the inspection.\nIn your March 3, 2025, written response, and in subsequent correspondence, you described corrective actions including but not limited to your engagement with a consultant to perform reviews of your pharmacovigilance processes and associated interfaces, as well as your deviation system and your corrective and preventive action system, to ensure that all cases have been reported to FDA and all deviations have been handled adequately. You also stated that your consultant is engaged in a retrospective review of all closed pharmacovigilance-related deviations dating back to June 2017, and that you have created a deviation review board. We acknowledge that your retrospective review of deviations is complete and that you have received the final report. For each major deviation that may affect compliance with PADE regulations and that has a Quality Assurance approval date after 01 Jan 2021, including those listed on the Deviations Handling request provided to the investigators during the inspection, you should submit a description of the deviation, date of identification, current status, the root-cause analysis, an assessment of the impact, the status of all corrective and preventive actions, and the timeline and results for effectiveness checks.\nWhile we acknowledge the corrective and preventive actions your firm has taken since our inspection, your response is inadequate because you did not provide sufficient details to determine whether your actions will effectively prevent similar violations in the future. Your explanations, when taken into consideration with the violations described above and your failure to adequately address your noncompliance, suggest systemic failures with your surveillance, receipt, evaluation, and reporting of ADEs to FDA. In addition, your failure to identify and assess the root cause(s) of deficiencies discussed in this letter raises concerns about your firm’s ability to monitor the safety of your products, including through oversight of vendors with whom you contract to fulfill any of your ADE responsibilities. While this inspection focused on NNI’s compliance with PADE regulations for a sample of NNI’s products, including semaglutide, liraglutide, nedosiran sodium, and estradiol, based on the nature of the inspection’s findings and your written response and correspondence, we have serious concerns about the scope and impact of these violations on your entire product portfolio.\nFDA relies on the complete, accurate, and timely submission of ADEs to monitor a product’s safety profile and uphold FDA’s mission to protect and promote public health. Reporting ADEs to FDA within the required time frames is necessary for the ongoing monitoring of drug safety profiles. Failure to report and investigate ADEs may limit the safety information that FDA may need when monitoring potential safety signals.\nWe emphasize that as an application holder, it is your responsibility to ensure that you comply with all applicable PADE requirements, including when you contract with a vendor to fulfill any of your ADE responsibilities. Your failure to develop procedures that ensure the submission of 15-day Alert reports and the prompt investigation of ADEs that were the subject of 15-day Alert reports raises significant concerns about your ability to accurately and completely report product safety information to the FDA in accordance with PADE requirements.\nThis letter is not intended to be an all-inclusive list of deficiencies that exist at NNI. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that you comply with FDA regulations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b) and allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action. If you believe you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\nShould you have any questions or concerns regarding this letter or the inspection, please email FDA at CDER-OSI-ADE@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\nDipti Kalra R.Ph., M.S., MBA Branch Chief\nPostmarketing Safety Branch\nDivision of Enforcement and Postmarketing Safety Office of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration Building 51, Room 5343\n10903 New Hampshire Avenue Silver Spring, MD 20993-0002\nSincerely,\n{See appended electronic signature page}\nDavid C. Burrow, Pharm.D., J.D. Director\nOffice of Scientific Investigations Office of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n--------------------------------------------------------------------------------------------\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n--------------------------------------------------------------------------------------------\n\u002Fs\u002F\n------------------------------------------------------------\nDAVID C BURROW\n03\u002F05\u002F2026 08:24:50 AM\n______________________\n\n1Argus is NNI’s drug safety database.","Novo Nordisk Inc.","novo-nordisk-inc-717576-03052026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnovo-nordisk-inc-717576-03052026","2026-10-26T08:09:35.346727+00:00","2026-03-10","717576","Mr. David S. Moore","2026-08-19T04:51:52.333+00:00","VIA UNITED PARCEL SERVICE AND VIA E-MAIL","26-HFD-45-03-01","2026-03-05",{"id":55,"raw":56,"subject":61,"body_html":62,"body_text":63,"firm_name":42,"letter_id":64,"created_at":65,"fei_number":19,"letter_url":66,"updated_at":67,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":69,"product_type":26,"closeout_date":19,"issuing_office":38,"recipient_name":70,"body_fetched_at":71,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},669,[57,58,59,38,60,13,13,13],"\u003Ctime datetime=\"2025-09-16T04:00:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-09T04:00:00Z\">09\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnovo-nordisk-inc-716495-09092025\">Novo Nordisk Inc.\u003C\u002Fa>","False &amp; Misleading Claims\u002FMisbranded","False & Misleading Claims\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Maziar Mike Doustdar\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Novo Nordisk Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>800 Scudders Mill Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Plainsboro\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08536\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>Dear Maziar Mike Doustdar:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) has reviewed the promotional communication, a direct-to-consumer video (video), titled “An Oprah Special: Shame, Blame, and the Weight Loss Revolution,” regarding WEGOVY (semaglutide) injection, for subcutaneous use (Wegovy), OZEMPIC ® (semaglutide) injection, for subcutaneous use (Ozempic), and VICTOZA® (liraglutide) injection, for subcutaneous use (Victoza). The video features Dr. W. Scott Butsch\u003Ca id=\"footnoteref1_mwwgl9j\" href=\"#footnote1_mwwgl9j\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp;and Dr. Amanda Velazquez\u003Ca id=\"footnoteref2_aygdtzp\" href=\"#footnote2_aygdtzp\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa>, paid consultants (representatives) who “receive research funding from companies making GLP-1\u003Ca id=\"footnoteref3_ylple0f\" href=\"#footnote3_ylple0f\">\u003Csup>3\u003C\u002Fsup>\u003C\u002Fa>&nbsp;drugs.”\u003Ca id=\"footnoteref4_78zrm4j\" href=\"#footnote4_78zrm4j\">\u003Csup>4\u003C\u002Fsup>\u003C\u002Fa>&nbsp;The video also features Negelle Morris,\u003Ca id=\"footnoteref5_4d004y4\" href=\"#footnote5_4d004y4\">\u003Csup>5\u003C\u002Fsup>\u003C\u002Fa>&nbsp;Senior Vice President of Cardiometabolic Sales for Novo Nordisk Inc. (Novo Nordisk). The video originally appeared on ABC as a Primetime Oprah Special on March 18, 2024 and can also be accessed through ABC’s website.\u003Ca id=\"footnoteref6_ug7zcgt\" href=\"#footnote6_ug7zcgt\">\u003Csup>6\u003C\u002Fsup>\u003C\u002Fa>&nbsp;The video subsequently appeared on Hulu on March 19, 2024. FDA has determined that the video is false or misleading. Thus, the video misbrands Wegovy, Ozempic, and Victoza within the meaning of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act) and makes its distribution violative. 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1 (e)(5); (e)(7)(viii). In addition, these materials were not submitted at the time of initial dissemination or publication as required by 21 CFR 314.81(b)(3)(i). These violations are concerning from a public health perspective because the promotional communication creates a misleading impression regarding the safety of Wegovy, Ozempic, and Victoza, which are drugs with multiple serious, potentially life-threatening risks, including a boxed warning for the risk of thyroid C-cell tumors. Obesity and excessive weight and type 2 diabetes mellitus are significant public health concerns that affect vulnerable populations (e.g., children) and millions of adults in the United States and are associated with numerous co-morbidities. Consumers and patients who seek medical treatment for managing obesity and excessive weight or their type 2 diabetes mellitus should receive truthful and nonmisleading information regarding the serious risks associated with the use of a weight management prescription drug product, such as Wegovy, and with the use of type 2 diabetes prescription drug products, such as Ozempic and Victoza.\u003C\u002Fp>\u003Cp>\u003Cstrong>Background\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Below are the indication and summary of the most serious and most common risks associated with the use of Wegovy, Ozempic, and Victoza.\u003Ca id=\"footnoteref7_j3ytxpd\" href=\"#footnote7_j3ytxpd\">\u003Csup>7\u003C\u002Fsup>\u003C\u002Fa>&nbsp;According to the INDICATIONS AND USAGE section of the respective FDA-approved prescribing information (PI)\u003Ca id=\"footnoteref8_yj6f25m\" href=\"#footnote8_yj6f25m\">\u003Csup>8\u003C\u002Fsup>\u003C\u002Fa>,\u003Ca id=\"footnoteref9_ar6m3te\" href=\"#footnote9_ar6m3te\">\u003Csup>9\u003C\u002Fsup>\u003C\u002Fa>,\u003Ca id=\"footnoteref10_6ed96ld\" href=\"#footnote10_6ed96ld\">\u003Csup>10\u003C\u002Fsup>\u003C\u002Fa>&nbsp;(in pertinent part):\u003C\u002Fp>\u003Cp>WEGOVY is indicated in combination with a reduced calorie diet and increased physical\u003Cbr>activity:\u003Cbr>• to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.\u003Cbr>• to reduce excess body weight and maintain weight reduction long term in:\u003Cbr>• Adults and pediatric patients aged 12 years and older with obesity\u003Cbr>• Adults with overweight in the presence of at least one weight-related comorbid condition.\u003C\u002Fp>\u003Cp>\u003Cu>Limitations of Use:\u003C\u002Fu>\u003Cbr>• WEGOVY contains semaglutide. Coadministration with other semaglutidecontaining products or with any other GLP-1 receptor agonist is not recommended.\u003C\u002Fp>\u003Cp>The PI for Wegovy contains a boxed warning regarding the risk of thyroid C-cell tumors. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); and in patients with a prior serious hypersensitivity reaction to semaglutide or any of the excipients in Wegovy. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with Wegovy. In addition, the PI for Wegovy includes warnings and precautions regarding acute pancreatitis, acute gallbladder disease, hypoglycemia, acute kidney injury, hypersensitivity reactions, diabetic retinopathy complications in patients with type 2 diabetes, heart rate increase, and suicidal behavior and ideation. The most common adverse reactions observed with Wegovy were nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis.\u003C\u002Fp>\u003Cp>OZEMPIC is indicated:\u003Cbr>• as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.\u003Cbr>• to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.\u003C\u002Fp>\u003Cp>\u003Cu>Limitations of Use:\u003C\u002Fu>\u003Cbr>• OZEMPIC has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.\u003Cbr>• OZEMPIC is not indicated for use in patients with type 1 diabetes mellitus.\u003C\u002Fp>\u003Cp>The PI for Ozempic contains a boxed warning regarding the risk of thyroid C-cell tumors. Ozempic is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2; and in patients with a serious hypersensitivity reaction to semaglutide or any of the excipients in Ozempic. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with Ozempic. In addition, the PI for Ozempic includes warnings and precautions regarding pancreatitis, diabetic retinopathy complications, never sharing an Ozempic pen between patients, hypoglycemia with concomitant use of insulin secretagogues or insulin, acute kidney injury, hypersensitivity reactions, and acute gallbladder disease. The most common adverse reactions observed with Ozempic were nausea, vomiting, diarrhea, abdominal pain, and constipation.\u003C\u002Fp>\u003Cp>VICTOZA is indicated:\u003Cbr>• as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.\u003Cbr>• to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.\u003C\u002Fp>\u003Cp>\u003Cu>Limitations of Use:\u003C\u002Fu>\u003Cbr>• VICTOZA should not be used in patients with type 1 diabetes mellitus.\u003Cbr>• VICTOZA contains liraglutide and should not be coadministered with other liraglutide-containing products.\u003C\u002Fp>\u003Cp>The PI for Victoza contains a boxed warning regarding the risk of thyroid C-cell tumors. Victoza is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2; and in patients with a serious hypersensitivity reaction to liraglutide or any of the excipients in Victoza. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with Victoza. In addition, the PI for Victoza includes warnings and precautions regarding pancreatitis, never sharing a Victoza pen between patients, hypoglycemia, acute kidney injury, hypersensitivity reactions, and acute gallbladder disease. The most common adverse reactions observed with Victoza were nausea, diarrhea, vomiting, decreased appetite, dyspepsia, and constipation.\u003C\u002Fp>\u003Cp>\u003Cu>Prior Communications\u003C\u002Fu>\u003C\u002Fp>\u003Cp>FDA notes that several advisory comments dated March 24, 2010, March 29, 2010, January 14, 2011, May 22, 2013, and April 22, 2016, to Novo Nordisk addressed draft promotional communications for Victoza with certain similarities to the video in this letter. Specifically, in the March 24, 2010 advisory comments, FDA recommended revising the draft promotional communication to avoid minimizing material risk information regarding the risk associated with Victoza. In the March 29, 2010 advisory comments, FDA recommended revising the draft promotional communication to avoid omitting material risk information regarding the risk of MTC and thyroid tumors, and warnings and precautions associated with gastrointestinal side effects and hypoglycemia. In the January 14, 2011 advisory comments, FDA recommended revising the draft promotional communications to avoid minimizing the warning and precaution of pancreatitis. In the May 22, 2013, advisory comments, FDA recommended revising the draft promotional communication to include important risk information regarding injection site reactions, symptoms of a serious allergic reaction associated with the use of Victoza, pancreatitis, and dehydration, or otherwise misrepresenting important risk information. In the April 22, 2016, advisory comments FDA recommended revising the draft promotional communication to avoid omitting material information regarding the risk of Victoza in patients with a personal or family history of MTC and warnings and precautions associated with gastrointestinal side effects and common side effects associated with Victoza, or otherwise misrepresenting important risk information.\u003C\u002Fp>\u003Cp>Additionally, FDA notes that our advisory comments dated May 7, 2018, to Novo Nordisk addressed a draft promotional communication for Ozempic with certain similarities to the video addressed in this letter. In these advisory comments, FDA recommended revising the draft promotional communication to avoid minimizing the boxed warning, or otherwise misrepresenting important risk information. FDA also notes that our advisory comments dated September 23, 2021, to Novo Nordisk addressed draft promotional communications for Wegovy with certain similarities to the video addressed in this letter. In these advisory comments, FDA recommended revising draft promotional communications to avoid minimizing the risk of increased risk of acute gallbladder disease and gastrointestinal adverse reactions associated with Wegovy, or otherwise misrepresenting important risk information.\u003C\u002Fp>\u003Cp>We are concerned that Novo Nordisk is promoting Wegovy, Ozempic, and Victoza in a manner that fails to present the serious risks of these drug products in a truthful and nonmisleading manner, despite FDA’s prior comments.\u003C\u002Fp>\u003Cp>\u003Cstrong>False or Misleading Risk Presentation\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Prescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading with respect to risk. The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in light of the representations made or with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication.\u003C\u002Fp>\u003Cp>The video is a 42-minute special program, hosted by Oprah Winfrey, concerning “the new drugs sparking... a weight loss revolution...that have captured the world’s attention”\u003Ca id=\"footnoteref11_8wx5tlp\" href=\"#footnote11_8wx5tlp\">\u003Csup>11\u003C\u002Fsup>\u003C\u002Fa>&nbsp;due to “so-called miracle medications like Ozempic, Wegovy, Mounjaro, and Zepbound.” The video features patient testimonials from those who struggle with obesity and excessive weight, including those who have used these drug products to help lose weight. One such patient testimonial, at approximately 21 minutes and 14 seconds, includes a mother and her teenage daughter who share their story of the daughter’s weight loss journey and experience with the use of GLP-1s in adolescence, specifically the use of Victoza.\u003C\u002Fp>\u003Cp>The video also prominently features two paid consultants of Novo Nordisk, Drs. Butsch and Velazquez,\u003Ca id=\"footnoteref12_ajto0y7\" href=\"#footnote12_ajto0y7\">\u003Csup>12\u003C\u002Fsup>\u003C\u002Fa>&nbsp;who are asked about their experiences with treating patients who are obese or have excess weight, and the use of these medications. The Novo Nordisk Vice President of Cardiometabolic Sales, Negelle Morris, is also featured at the end of the video to discuss access to Novo Nordisk drug products: Wegovy, Ozempic, and Victoza. At approximately 12 minutes and 30 seconds into the video, Ms. Winfrey introduces Dr. Butsch using a prerecorded cut-away where he provides information to the audience about some of the causes for the high rates of obesity in the United States and the complexity of obesity as a medical condition. Ms. Winfrey then introduces Dr. Velazquez at approximately 16 minutes and 40 seconds using another pre-recorded cut-away with the preface that they will now ask “how these medications actually work.” Dr. Velazquez describes in the cut-away how the “newer agents like GLP-1s” are a “new era for the treatment of obesity.” While Dr. Velazquez is speaking, a photo of an Ozempic pen is displayed on screen. Dr. Velazquez continues by describing how our naturally occurring GLP-1 hormone works in the body and how drugs, like Wegovy, Ozempic, and Victoza are “essentially copying what our normal GLP-1 hormone does in our body, but doing it a little bit better.” Throughout the remainder of the cut-away, Dr. Velazquez provides more details about the clinical and metabolic processes associated with GLP-1s and how these medications, compared to previous obesity and excessive weight treatments, have achieved “double the amount of weight loss.” Ms. Winfrey then continues the conversation with both Drs. Butsch and Velazquez on-stage about the benefits of the medications, and then concludes this segment of the video (20:05) by asking “You are both consultants for the drug companies, what does that mean?” Dr. Velazquez answers that “…they are looking for our expert opinion to be able to deliver high quality care to patients” and Dr. Butsch further states “I’ve been involved with some of these companies in developing educational programs and modules for medical students and medical trainees to learn more about the disease of obesity. I’m also running clinical trials with future medications.”\u003C\u002Fp>\u003Cp>The video includes numerous representations about the benefits of Wegovy, Ozempic, and Victoza made by representatives of Novo Nordisk, but omits important risk information and otherwise minimizes the risks of these drug products. We acknowledge that the video includes a segment on “the side effects” of GLP-1s, generally (beginning at 33:35 and ending at 37:47). However, this segment begins with comments from a non-Novo Nordisk affiliated health care provider about how patients should be weighing the risks and benefits of taking any drug and, as explained below, concludes after several misleading statements and omissions by representatives of Novo Nordisk about the risks of Wegovy, Ozempic, and Victoza.\u003Ca id=\"footnoteref13_nsffga2\" href=\"#footnote13_nsffga2\">\u003Csup>13\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fp>\u003Cp>First, the video omits an important concept from the boxed warning for these drugs; specifically the contraindication in patients with a personal or family history of MEN 2 due to the risk of thyroid c-cell tumors. While Dr. Velazquez does provide a limited discussion of the thyroid cancer risk to “anybody [who] has a history specifically of medullary thyroid cancer,” the risk to patients with a history of MEN 2 is omitted. The boxed warning in the Wegovy, Ozempic, and Victoza PIs states the following (in pertinent part; bolded emphasis original, underlined emphasis added):\u003C\u002Fp>\u003Cp>\u003Cstrong>WEGOVY [and OZEMPIC and VICTOZA] is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) . . . . Counsel patients regarding the potential risk for MTC with the use of WEGOVY [and OZEMPIC and VICTOZA] and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, several warnings and precautions associated with Wegovy, Ozempic, and Victoza are completely omitted from the video. Specifically, serious risks pertaining to hypoglycemia, acute kidney injury, hypersensitivity reactions, diabetic retinopathy complications in patients with type 2 diabetes, heart rate increase, and suicidal behavior and ideation, which are described in the “\u003Cstrong>What are the possible side effects of WEGOVY?\u003C\u002Fstrong>” section of the Wegovy Medication Guide, are omitted from the video. Similarly, the serious risks to patients treated with Ozempic pertaining to diabetic retinopathy complications, shar[ing] an Ozempic pen between patients, hypoglycemia, acute kidney injury, and hypersensitivity reactions are also omitted from the video. Furthermore, similar warnings and precautions for Victoza, as described in the “\u003Cstrong>What are the possible side effects of VICTOZA?\u003C\u002Fstrong>” section of the Medication Guide, are also omitted from the video.\u003C\u002Fp>\u003Cp>These omissions are further exacerbated by statements from Dr. Velazquez in the video that misleadingly minimize and downplay the drugs’ boxed warning, contraindications, warnings and precautions and other common adverse events. For example, when Ms. Winfrey asks about the “serious health effects down the road” from treatment with GLP-1 medications, like Wegovy, Ozempic, and Victoza (36:56), Dr. Velazquez responds with the following (emphasis added):\u003C\u002Fp>\u003Cp>• “There’s been a lot of hype around like pancreatitis, gallbladder complications, concerns for thyroid cancer. This has really not been shown in human studies that this is a downstream complication, and that really the risk is less than 1%.” (37:00)\u003Cbr>• “If anybody has a history specifically of MTC... is very, very rare. So if they do have that, we are not prescribing that medication. So, we have to be able to keep up with knowing the data, and recognizing that it’s rare, but it’s there and we have to always screen.” (37:19)\u003C\u002Fp>\u003Cp>Dr. Velazquez’s description of the incidence of MTC in patients treated with GLP-1 drugs is misleading when she states, “this has really not been shown in human studies” and is “very, very rare.” According to the WARNINGS AND PRECAUTIONS, Risk of Thyroid C-cell Tumors, section of the Victoza PI “cases of MTC have been reported in the postmarketing period in patients treated with Victoza”. While we acknowledge that current data is insufficient to establish or exclude a causal relationship between MTC and GLP-1s, it is misleading to describe this risk as having “…not been shown in human studies” and as “very, very rare” since the risk of thyroid C-cell tumors, including MTC and MEN 2, is a boxed warning across the entire GLP-1 pharmacological class.\u003C\u002Fp>\u003Cp>These statements are also concerning because they misleadingly minimize the serious risks associated with Wegovy, Ozempic, and Victoza by suggesting that a patient does not need to be worried about the potential for developing “pancreatitis,” “gallbladder complications,” and “thyroid cancer” from treatment with Wegovy, Ozempic, and Victoza. Specifically, the statements that “there’s been a lot of hype” about the risks and they are “rare, but…there” are especially egregious, given the nature of the risks to patients from GLP-1 treatment, including pancreatitis, which has led to serious complications, such as organ failure and death. According to the WARNINGS AND PRECAUTIONS, Acute Pancreatitis, section of the Wegovy PI, “acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide.” Moreover, the “gallbladder complications” documented in clinical trials for Wegovy, Ozempic, and Victoza also led to serious complications in some patients and required hospitalization or cholecystectomy (gallbladder removal).\u003C\u002Fp>\u003Cp>Additional statements in the video, with respect to the common adverse reactions for Wegovy, Ozempic, and Victoza, are similarly misleading since they suggest that Wegovy, Ozempic, and Victoza are safer because the adverse events are less common and less severe than have been demonstrated. For example, when asked to respond to the concerns of a guest patient that experienced side effects from using GLP-1s and subsequently had to discontinue treatment, the following conversation occurs (emphasis added):\u003C\u002Fp>\u003Cp>• Ms. Winfrey: (after speaking to the guest patient “Rolanda” about her need to discontinue treatment with a GLP-1 medication due to side effects such as becoming “very nauseous” and vomiting blood) “So Dr. Velazquez, what do you have to say about that?” (36:37)\u003Cbr>• Dr. Velazquez: “Yeah, I think that’s about education of the side effects. It’s about effective management of the side effects.” (36:42)\u003Cbr>• Ms. Winfrey: “But they do have side effects?” (36:46)\u003Cbr>• Dr. Velazquez: “I think that they’ve gotten overhyped. Medicines have side effects, but the important part is that they’re mild to moderate in the research studies.” (36:48)\u003Cbr>• Dr. Butsch: “Yeah.” while nodding affirmatively in response to Dr. Velazquez (36:53)\u003C\u002Fp>\u003Cp>These statements further compound the misleading minimization of the risks for Wegovy, Ozempic, and Victoza (particularly the common adverse events), by suggesting such risks are “overhyped.” The use of phrases such as “a lot of hype” and “overhyped” when referring to risk information misleadingly undermines the risk’s importance and severity.\u003Ca id=\"footnoteref14_0ttck92\" href=\"#footnote14_0ttck92\">\u003Csup>14\u003C\u002Fsup>\u003C\u002Fa>&nbsp;These statements also minimize the risks by describing them as “mild to moderate,” when this has not been demonstrated. Similar to the guest patient who was the subject of the above conversation, a number of patients in clinical trials taking GLP-1s, such as Wegovy, Ozempic, and Victoza, experienced adverse events, some of which were so severe that patients discontinued use of the drug. For example, according to the ADVERSE REACTIONS, Gastrointestinal Adverse Reactions section of the Wegovy PI (in pertinent part, emphasis added):\u003C\u002Fp>\u003Cp>\u003Cu>In clinical trials in adults, 73% of WEGOVY-treated patients\u003C\u002Fu> and 47% of patients receiving placebo reported gastrointestinal adverse reactions, \u003Cu>including severe reactions\u003C\u002Fu> that were reported more frequently among patients receiving WEGOVY (4.1%) than placebo (0.9%). The most frequently reported reactions were nausea (44% vs. 16%), vomiting (25% vs. 6%) and diarrhea (30% vs. 16%).\u003Cbr>. . . .\u003Cbr>\u003Cu>In the pediatric clinical trial, 62% of WEGOVY-treated patients\u003C\u002Fu> and 42% of placebotreated patients reported gastrointestinal disorders. The most frequently reported reactions were nausea (42% vs. 18%), vomiting (36% vs. 10%), and diarrhea (22% vs. 19%). Other gastrointestinal-related reactions that occurred at a higher incidence than placebo among WEGOVY-treated patients included abdominal pain, constipation, eructation, gastroesophageal reflux disease, and flatulence.\u003Cbr>. . . .\u003Cbr>\u003Cu>Permanent discontinuation of treatment as a result of a gastrointestinal adverse reaction occurred in 4.3% of WEGOVY-treated adult patients\u003C\u002Fu> versus 0.7% of placebo-treated patients.\u003C\u002Fp>\u003Cp>In addition, according to the ADVERSE REACTIONS, Gastrointestinal Adverse Reactions section of the Ozempic PI (in pertinent part, emphasis added):\u003C\u002Fp>\u003Cp>In the pool of placebo-controlled trials, \u003Cu>gastrointestinal adverse reactions occurred more frequently among patients receiving OZEMPIC than placebo (placebo 15.3%, OZEMPIC 0.5 mg 32.7%, OZEMPIC 1 mg 36.4%)\u003C\u002Fu>. The majority of reports of nausea, vomiting, and\u002For diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%).\u003C\u002Fp>\u003Cp>Similarly, according to the ADVERSE REACTIONS, Gastrointestinal Adverse Reactions section of the Victoza PI (in pertinent part, emphasis added):\u003C\u002Fp>\u003Cp>\u003Cu>In the pool of 5 glycemic control, placebo-controlled adult clinical trials, withdrawals due to gastrointestinal adverse reactions, occurred in 4.3% of VICTOZA-treated patients\u003C\u002Fu> and 0.5% of placebo-treated patients. Withdrawal due to gastrointestinal adverse events mainly occurred during the first 2-3 months of the trials.\u003C\u002Fp>\u003Cp>Moreover, the statement that “medicines have side effects,” coupled with the statement that GLP-1 side effects are “mild to moderate,” further downplays the serious nature of the risks associated with GLP-1s, like Wegovy, Ozempic, and Victoza, by suggesting that because all drugs generally have side effects, that the individual risks of GLP-1s are no more than other drugs and are therefore of little concern. There are several additional common adverse reactions, some of which were severe in nature (i.e., hypoglycemia), that were observed with Wegovy, Ozempic, and Victoza; but, as noted above, were omitted entirely from the video. Therefore, it is misleading to represent that the side effects of GLP-1s, like Wegovy, Ozempic, and Victoza, are generally “mild to moderate.”\u003C\u002Fp>\u003Cp>The video not only omits several serious and significant risks; it also understates the minimal safety information that is disclosed, thus misrepresenting the safety profile of these drugs. By suggesting that safety or tolerability issues are “overhyped,” and by implying that these products are not associated with the serious and significant risks outlined above, the video misrepresents the safety profile of Wegovy, Ozempic, and Victoza. This implication is false or misleading and raises significant public health and safety concerns.\u003C\u002Fp>\u003Cp>Finally, the video is misleading because it fails to present information related to the side effects and contraindications for Wegovy, Ozempic, and Victoza with a prominence and readability reasonably comparable with the presentation of information relating to the benefits of Wegovy, Ozempic, and Victoza. As noted, the video contains numerous representations and suggestions about the benefits of Wegovy, Ozempic, and Victoza, while the risk information is relegated to the end of the video and briefly discussed. Of the 42-minute video, only four minutes in total are devoted to the important shared risks associated with GLP-1s, like Wegovy, Ozempic, and Victoza. Additionally, the video does not provide any signal to alert the viewer where they may be able to find additional risk information about the drugs. The overall effect of disclosing risk information in this limited manner undermines the communication of risk information and thereby misleadingly minimizes the risks associated with the use of Wegovy, Ozempic, and Victoza.\u003C\u002Fp>\u003Cp>\u003Cstrong>Failure to Submit Under Form FDA-2253\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA regulations require any labeling or advertising devised for promotion of the drug product to be submitted at the time of initial dissemination of the labeling and at the time of initial publication of the advertisement for a prescription drug product. Each submission is required to be accompanied by a completed transmittal Form FDA-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) and is required to include a copy of the product’s current professional labeling. A copy of the video was not submitted to FDA under cover of Form FDA-2253 at the time of initial publication as required by 21 CFR 314.81(b)(3)(i).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Action\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For the reasons discussed above, the video misbrands Wegovy, Ozempic, and Victoza and makes the distribution of the drug in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act). 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1 (e)(5). In addition, these materials were not submitted at the time of initial dissemination or publication as required by 21 CFR 314.81(b)(3)(i).\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. You should take immediate action to address any violations (including, for example, ceasing and desisting promotional communications that are misleading as described above). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction. Please submit a written response to this letter within 15 working days from the date of receipt, addressing the concerns described in this letter, listing all other promotional communications (with the 2253 submission date) for Wegovy, Ozempic, and Victoza that contain representations such as those described above, and explaining your plan for discontinuation of such communications, or for ceasing distribution of Wegovy, Ozempic, and Victoza.\u003C\u002Fp>\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\u003C\u002Fp>\u003Cp>Additionally, we request that your submission include a comprehensive plan of action to disseminate truthful, non-misleading, and complete corrective communication(s) about the concern(s) discussed in this letter. The corrective communication(s) should be disseminated to the audience(s) that received the promotional communication(s) identified in the opening paragraph of this letter. We recommend that corrective communication(s) include a description of the promotional communication(s) identified in this letter, which misbrand Wegovy, Ozempic, and Victoza; include a summary of the concern(s) described in this letter; and provide information to correct each of these concern(s). Corrective communication(s) should be free of promotional claims and presentations. To the extent possible, corrective communication(s) should be distributed using the same media, and generally for the same duration of time and with the same frequency as the promotional communication(s) identified in the opening paragraph of this letter.\u003C\u002Fp>\u003Cp>The concerns discussed in this letter do not necessarily constitute an exhaustive list of potential violations. It is your responsibility to ensure compliance with each applicable requirement of the FD&amp;C Act and FDA implementing regulations.\u003C\u002Fp>\u003Cp>Please direct your response to the \u003Cstrong>Food and Drug Administration, Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-B Ammendale Road, Beltsville, Maryland 20705-1266\u003C\u002Fstrong>. A courtesy copy can be sent by facsimile to (301) 847-8444. Please refer to MA 774, MA 1352, and MA 2028 in addition to the NDA numbers in all future correspondence relating to this particular matter. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. You are encouraged, but not required, to submit your response in eCTD format. All correspondence submitted in response to this letter should be placed under eCTD Heading 1.15.1.6. Questions related to the submission of your response letter should be emailed to CDEROPDP-RPM@fda.hhs.gov.\u003C\u002Fp>\u003Cp>\u003Cbr>Sincerely,\u003Cbr>{See appended electronic signature page}\u003Cbr>George Tidmarsh, M.D., Ph.D.\u003Cbr>Director\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>\u002Fs\u002F\u003Cbr>------------------------------------------------------------\u003Cbr>CARTER M BEACH\u003Cbr>09\u002F09\u002F2025 05:18:24 PM\u003Cbr>On behalf of George Tidmarsh, M.D., Ph.D\u003C\u002Fp>\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F188775\u002Fdownload?attachment\">Promotional Material\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_mwwgl9j\">\u003Ca href=\"#footnoteref1_mwwgl9j\">1\u003C\u002Fa>Dr. W. Scott Butsch is a health care provider who serves as the Director of Obesity Medicine at the Bariatric\nInstitute of Cleveland Clinic. Dr. Butsch has financial and consultancy connections to Novo Nordisk. Based on\ncurrently available data, from 2017-2023, the Centers for Medicare and Medicaid Services Open Payments Data\nwebsite reports that Dr. Butsch has received (b)(4) in consulting fees, grants, and other payments from\nNovo Nordisk (https:\u002F\u002Fopenpaymentsdata.cms.gov\u002Fphysician\u002F1050529).\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_aygdtzp\">\u003Ca href=\"#footnoteref2_aygdtzp\">2\u003C\u002Fa>Dr. Amanda Velazquez is a health care provider who serves as the Director of Obesity Medicine at Cedars-\nSinai Medical Center. Dr. Velazquez has financial and consultancy connections to Novo Nordisk. Based on\ncurrently available data, from 2019-2023, the Centers for Medicare and Medicaid Services Open Payments Data\nwebsite reports that Dr. Velazquez has received (b)(4) in consulting fees, grants, and other payments\nfrom Novo Nordisk (https:\u002F\u002Fopenpaymentsdata.cms.gov\u002Fphysician\u002F439627).\u003C\u002Fli>\n                      \u003Cli id=\"footnote3_ylple0f\">\u003Ca href=\"#footnoteref3_ylple0f\">3\u003C\u002Fa>GLP-1 = Glucagon-like Peptide-1\u003C\u002Fli>\n                      \u003Cli id=\"footnote4_78zrm4j\">\u003Ca href=\"#footnoteref4_78zrm4j\">4\u003C\u002Fa>At approximately 20 minutes and 46 seconds, the video includes the following prominent on-screen text: “Dr.\nButsch and Dr. Velazquez consult for and receive research funding from companies making GLP-1 drugs.”\u003C\u002Fli>\n                      \u003Cli id=\"footnote5_4d004y4\">\u003Ca href=\"#footnoteref5_4d004y4\">5\u003C\u002Fa>Negelle Morris is Senior Vice President, Novo Nordisk Inc. (NNI) Cardiometabolic Sales.\nhttps:\u002F\u002Fwww.novonordisk-us.com\u002Fabout\u002Four-executive-team\u002Fnegelle-morris.html\u003C\u002Fli>\n                      \u003Cli id=\"footnote6_ug7zcgt\">\u003Ca href=\"#footnoteref6_ug7zcgt\">6\u003C\u002Fa>This video is available on the internet at https:\u002F\u002Fabc.com\u002Fshows\u002Fan-oprah-special-shame-blame-and-theweight-\nloss-revolution\u002Fepisode-guide\u002Fseason-01\u002F01-an-oprah-special-shame-blame-and-the-weight-lossrevolution\n(last accessed date September 8, 2025)\u003C\u002Fli>\n                      \u003Cli id=\"footnote7_j3ytxpd\">\u003Ca href=\"#footnoteref7_j3ytxpd\">7\u003C\u002Fa>This information is for background purposes only and does not necessarily represent the risk information that\nshould be included in the promotional communication(s) cited in this letter.\u003C\u002Fli>\n                      \u003Cli id=\"footnote8_yj6f25m\">\u003Ca href=\"#footnoteref8_yj6f25m\">8\u003C\u002Fa>The version of the Wegovy PI referred to in this letter is dated March 2024.\u003C\u002Fli>\n                      \u003Cli id=\"footnote9_ar6m3te\">\u003Ca href=\"#footnoteref9_ar6m3te\">9\u003C\u002Fa>The version of the Ozempic PI referred to in this letter is dated September 2023.\u003C\u002Fli>\n                      \u003Cli id=\"footnote10_6ed96ld\">\u003Ca href=\"#footnoteref10_6ed96ld\">10\u003C\u002Fa>The version of the Victoza PI referred to in this letter is dated July 2023.\u003C\u002Fli>\n                      \u003Cli id=\"footnote11_8wx5tlp\">\u003Ca href=\"#footnoteref11_8wx5tlp\">11\u003C\u002Fa>The entirety of this video is focused on weight loss and weight loss products, specifically GLP-1s. While\ndiabetes is briefly mentioned, the majority of the program focuses on weight loss. Ozempic and Victoza are not\nFDA-approved for weight loss.\u003C\u002Fli>\n                      \u003Cli id=\"footnote12_ajto0y7\">\u003Ca href=\"#footnoteref12_ajto0y7\">12\u003C\u002Fa>See supra footnotes 1, 2, and 3.\u003C\u002Fli>\n                      \u003Cli id=\"footnote13_nsffga2\">\u003Ca href=\"#footnoteref13_nsffga2\">13\u003C\u002Fa>We note that shortly after the segment on side effects, Ms. Morris was introduced (38:19) as Vice President of\nSales for Novo Nordisk. Although Ms. Morris appeared to be present during the filming of the side effects\nsegment video, Ms. Morris made no additions to the limited risk presentation or interjected any corrections to the\nmisleading representations made by the previous representatives of Novo Nordisk.\u003C\u002Fli>\n                      \u003Cli id=\"footnote14_0ttck92\">\u003Ca href=\"#footnoteref14_0ttck92\">14\u003C\u002Fa>While these and other statements made by Dr. Velazquez may be a reflection of their experience as a health\ncare provider treating patients with GLP-1s, like Wegovy, Ozempic and Victoza, their personal experience does\nnot support the representation in a promotional communication regarding the benefits of these drugs that the\nserious risks associated with Wegovy, Ozempic, and Victoza have received “a lot of hype” or have been\n“overhyped.”\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMaziar Mike Doustdar\n\nRecipient Title\n\nPresident and Chief Executive Officer\n\nNovo Nordisk Inc.\n\n800 Scudders Mill Road\n\nPlainsboro, NJ 08536\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nDear Maziar Mike Doustdar:\nThe U.S. Food and Drug Administration (FDA) has reviewed the promotional communication, a direct-to-consumer video (video), titled “An Oprah Special: Shame, Blame, and the Weight Loss Revolution,” regarding WEGOVY (semaglutide) injection, for subcutaneous use (Wegovy), OZEMPIC ® (semaglutide) injection, for subcutaneous use (Ozempic), and VICTOZA® (liraglutide) injection, for subcutaneous use (Victoza). The video features Dr. W. Scott Butsch1 and Dr. Amanda Velazquez2, paid consultants (representatives) who “receive research funding from companies making GLP-13 drugs.”4 The video also features Negelle Morris,5 Senior Vice President of Cardiometabolic Sales for Novo Nordisk Inc. (Novo Nordisk). The video originally appeared on ABC as a Primetime Oprah Special on March 18, 2024 and can also be accessed through ABC’s website.6 The video subsequently appeared on Hulu on March 19, 2024. FDA has determined that the video is false or misleading. Thus, the video misbrands Wegovy, Ozempic, and Victoza within the meaning of the Federal Food, Drug and Cosmetic Act (FD&C Act) and makes its distribution violative. 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1 (e)(5); (e)(7)(viii). In addition, these materials were not submitted at the time of initial dissemination or publication as required by 21 CFR 314.81(b)(3)(i). These violations are concerning from a public health perspective because the promotional communication creates a misleading impression regarding the safety of Wegovy, Ozempic, and Victoza, which are drugs with multiple serious, potentially life-threatening risks, including a boxed warning for the risk of thyroid C-cell tumors. Obesity and excessive weight and type 2 diabetes mellitus are significant public health concerns that affect vulnerable populations (e.g., children) and millions of adults in the United States and are associated with numerous co-morbidities. Consumers and patients who seek medical treatment for managing obesity and excessive weight or their type 2 diabetes mellitus should receive truthful and nonmisleading information regarding the serious risks associated with the use of a weight management prescription drug product, such as Wegovy, and with the use of type 2 diabetes prescription drug products, such as Ozempic and Victoza.\nBackground\nBelow are the indication and summary of the most serious and most common risks associated with the use of Wegovy, Ozempic, and Victoza.7 According to the INDICATIONS AND USAGE section of the respective FDA-approved prescribing information (PI)8,9,10 (in pertinent part):\nWEGOVY is indicated in combination with a reduced calorie diet and increased physical\nactivity:\n• to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.\n• to reduce excess body weight and maintain weight reduction long term in:\n• Adults and pediatric patients aged 12 years and older with obesity\n• Adults with overweight in the presence of at least one weight-related comorbid condition.\nLimitations of Use:\n• WEGOVY contains semaglutide. Coadministration with other semaglutidecontaining products or with any other GLP-1 receptor agonist is not recommended.\nThe PI for Wegovy contains a boxed warning regarding the risk of thyroid C-cell tumors. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); and in patients with a prior serious hypersensitivity reaction to semaglutide or any of the excipients in Wegovy. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with Wegovy. In addition, the PI for Wegovy includes warnings and precautions regarding acute pancreatitis, acute gallbladder disease, hypoglycemia, acute kidney injury, hypersensitivity reactions, diabetic retinopathy complications in patients with type 2 diabetes, heart rate increase, and suicidal behavior and ideation. The most common adverse reactions observed with Wegovy were nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis.\nOZEMPIC is indicated:\n• as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.\n• to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.\nLimitations of Use:\n• OZEMPIC has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.\n• OZEMPIC is not indicated for use in patients with type 1 diabetes mellitus.\nThe PI for Ozempic contains a boxed warning regarding the risk of thyroid C-cell tumors. Ozempic is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2; and in patients with a serious hypersensitivity reaction to semaglutide or any of the excipients in Ozempic. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with Ozempic. In addition, the PI for Ozempic includes warnings and precautions regarding pancreatitis, diabetic retinopathy complications, never sharing an Ozempic pen between patients, hypoglycemia with concomitant use of insulin secretagogues or insulin, acute kidney injury, hypersensitivity reactions, and acute gallbladder disease. The most common adverse reactions observed with Ozempic were nausea, vomiting, diarrhea, abdominal pain, and constipation.\nVICTOZA is indicated:\n• as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.\n• to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.\nLimitations of Use:\n• VICTOZA should not be used in patients with type 1 diabetes mellitus.\n• VICTOZA contains liraglutide and should not be coadministered with other liraglutide-containing products.\nThe PI for Victoza contains a boxed warning regarding the risk of thyroid C-cell tumors. Victoza is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2; and in patients with a serious hypersensitivity reaction to liraglutide or any of the excipients in Victoza. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with Victoza. In addition, the PI for Victoza includes warnings and precautions regarding pancreatitis, never sharing a Victoza pen between patients, hypoglycemia, acute kidney injury, hypersensitivity reactions, and acute gallbladder disease. The most common adverse reactions observed with Victoza were nausea, diarrhea, vomiting, decreased appetite, dyspepsia, and constipation.\nPrior Communications\nFDA notes that several advisory comments dated March 24, 2010, March 29, 2010, January 14, 2011, May 22, 2013, and April 22, 2016, to Novo Nordisk addressed draft promotional communications for Victoza with certain similarities to the video in this letter. Specifically, in the March 24, 2010 advisory comments, FDA recommended revising the draft promotional communication to avoid minimizing material risk information regarding the risk associated with Victoza. In the March 29, 2010 advisory comments, FDA recommended revising the draft promotional communication to avoid omitting material risk information regarding the risk of MTC and thyroid tumors, and warnings and precautions associated with gastrointestinal side effects and hypoglycemia. In the January 14, 2011 advisory comments, FDA recommended revising the draft promotional communications to avoid minimizing the warning and precaution of pancreatitis. In the May 22, 2013, advisory comments, FDA recommended revising the draft promotional communication to include important risk information regarding injection site reactions, symptoms of a serious allergic reaction associated with the use of Victoza, pancreatitis, and dehydration, or otherwise misrepresenting important risk information. In the April 22, 2016, advisory comments FDA recommended revising the draft promotional communication to avoid omitting material information regarding the risk of Victoza in patients with a personal or family history of MTC and warnings and precautions associated with gastrointestinal side effects and common side effects associated with Victoza, or otherwise misrepresenting important risk information.\nAdditionally, FDA notes that our advisory comments dated May 7, 2018, to Novo Nordisk addressed a draft promotional communication for Ozempic with certain similarities to the video addressed in this letter. In these advisory comments, FDA recommended revising the draft promotional communication to avoid minimizing the boxed warning, or otherwise misrepresenting important risk information. FDA also notes that our advisory comments dated September 23, 2021, to Novo Nordisk addressed draft promotional communications for Wegovy with certain similarities to the video addressed in this letter. In these advisory comments, FDA recommended revising draft promotional communications to avoid minimizing the risk of increased risk of acute gallbladder disease and gastrointestinal adverse reactions associated with Wegovy, or otherwise misrepresenting important risk information.\nWe are concerned that Novo Nordisk is promoting Wegovy, Ozempic, and Victoza in a manner that fails to present the serious risks of these drug products in a truthful and nonmisleading manner, despite FDA’s prior comments.\nFalse or Misleading Risk Presentation\nPrescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading with respect to risk. The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in light of the representations made or with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication.\nThe video is a 42-minute special program, hosted by Oprah Winfrey, concerning “the new drugs sparking... a weight loss revolution...that have captured the world’s attention”11 due to “so-called miracle medications like Ozempic, Wegovy, Mounjaro, and Zepbound.” The video features patient testimonials from those who struggle with obesity and excessive weight, including those who have used these drug products to help lose weight. One such patient testimonial, at approximately 21 minutes and 14 seconds, includes a mother and her teenage daughter who share their story of the daughter’s weight loss journey and experience with the use of GLP-1s in adolescence, specifically the use of Victoza.\nThe video also prominently features two paid consultants of Novo Nordisk, Drs. Butsch and Velazquez,12 who are asked about their experiences with treating patients who are obese or have excess weight, and the use of these medications. The Novo Nordisk Vice President of Cardiometabolic Sales, Negelle Morris, is also featured at the end of the video to discuss access to Novo Nordisk drug products: Wegovy, Ozempic, and Victoza. At approximately 12 minutes and 30 seconds into the video, Ms. Winfrey introduces Dr. Butsch using a prerecorded cut-away where he provides information to the audience about some of the causes for the high rates of obesity in the United States and the complexity of obesity as a medical condition. Ms. Winfrey then introduces Dr. Velazquez at approximately 16 minutes and 40 seconds using another pre-recorded cut-away with the preface that they will now ask “how these medications actually work.” Dr. Velazquez describes in the cut-away how the “newer agents like GLP-1s” are a “new era for the treatment of obesity.” While Dr. Velazquez is speaking, a photo of an Ozempic pen is displayed on screen. Dr. Velazquez continues by describing how our naturally occurring GLP-1 hormone works in the body and how drugs, like Wegovy, Ozempic, and Victoza are “essentially copying what our normal GLP-1 hormone does in our body, but doing it a little bit better.” Throughout the remainder of the cut-away, Dr. Velazquez provides more details about the clinical and metabolic processes associated with GLP-1s and how these medications, compared to previous obesity and excessive weight treatments, have achieved “double the amount of weight loss.” Ms. Winfrey then continues the conversation with both Drs. Butsch and Velazquez on-stage about the benefits of the medications, and then concludes this segment of the video (20:05) by asking “You are both consultants for the drug companies, what does that mean?” Dr. Velazquez answers that “…they are looking for our expert opinion to be able to deliver high quality care to patients” and Dr. Butsch further states “I’ve been involved with some of these companies in developing educational programs and modules for medical students and medical trainees to learn more about the disease of obesity. I’m also running clinical trials with future medications.”\nThe video includes numerous representations about the benefits of Wegovy, Ozempic, and Victoza made by representatives of Novo Nordisk, but omits important risk information and otherwise minimizes the risks of these drug products. We acknowledge that the video includes a segment on “the side effects” of GLP-1s, generally (beginning at 33:35 and ending at 37:47). However, this segment begins with comments from a non-Novo Nordisk affiliated health care provider about how patients should be weighing the risks and benefits of taking any drug and, as explained below, concludes after several misleading statements and omissions by representatives of Novo Nordisk about the risks of Wegovy, Ozempic, and Victoza.13\nFirst, the video omits an important concept from the boxed warning for these drugs; specifically the contraindication in patients with a personal or family history of MEN 2 due to the risk of thyroid c-cell tumors. While Dr. Velazquez does provide a limited discussion of the thyroid cancer risk to “anybody [who] has a history specifically of medullary thyroid cancer,” the risk to patients with a history of MEN 2 is omitted. The boxed warning in the Wegovy, Ozempic, and Victoza PIs states the following (in pertinent part; bolded emphasis original, underlined emphasis added):\nWEGOVY [and OZEMPIC and VICTOZA] is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) . . . . Counsel patients regarding the potential risk for MTC with the use of WEGOVY [and OZEMPIC and VICTOZA] and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).\nAdditionally, several warnings and precautions associated with Wegovy, Ozempic, and Victoza are completely omitted from the video. Specifically, serious risks pertaining to hypoglycemia, acute kidney injury, hypersensitivity reactions, diabetic retinopathy complications in patients with type 2 diabetes, heart rate increase, and suicidal behavior and ideation, which are described in the “What are the possible side effects of WEGOVY?” section of the Wegovy Medication Guide, are omitted from the video. Similarly, the serious risks to patients treated with Ozempic pertaining to diabetic retinopathy complications, shar[ing] an Ozempic pen between patients, hypoglycemia, acute kidney injury, and hypersensitivity reactions are also omitted from the video. Furthermore, similar warnings and precautions for Victoza, as described in the “What are the possible side effects of VICTOZA?” section of the Medication Guide, are also omitted from the video.\nThese omissions are further exacerbated by statements from Dr. Velazquez in the video that misleadingly minimize and downplay the drugs’ boxed warning, contraindications, warnings and precautions and other common adverse events. For example, when Ms. Winfrey asks about the “serious health effects down the road” from treatment with GLP-1 medications, like Wegovy, Ozempic, and Victoza (36:56), Dr. Velazquez responds with the following (emphasis added):\n• “There’s been a lot of hype around like pancreatitis, gallbladder complications, concerns for thyroid cancer. This has really not been shown in human studies that this is a downstream complication, and that really the risk is less than 1%.” (37:00)\n• “If anybody has a history specifically of MTC... is very, very rare. So if they do have that, we are not prescribing that medication. So, we have to be able to keep up with knowing the data, and recognizing that it’s rare, but it’s there and we have to always screen.” (37:19)\nDr. Velazquez’s description of the incidence of MTC in patients treated with GLP-1 drugs is misleading when she states, “this has really not been shown in human studies” and is “very, very rare.” According to the WARNINGS AND PRECAUTIONS, Risk of Thyroid C-cell Tumors, section of the Victoza PI “cases of MTC have been reported in the postmarketing period in patients treated with Victoza”. While we acknowledge that current data is insufficient to establish or exclude a causal relationship between MTC and GLP-1s, it is misleading to describe this risk as having “…not been shown in human studies” and as “very, very rare” since the risk of thyroid C-cell tumors, including MTC and MEN 2, is a boxed warning across the entire GLP-1 pharmacological class.\nThese statements are also concerning because they misleadingly minimize the serious risks associated with Wegovy, Ozempic, and Victoza by suggesting that a patient does not need to be worried about the potential for developing “pancreatitis,” “gallbladder complications,” and “thyroid cancer” from treatment with Wegovy, Ozempic, and Victoza. Specifically, the statements that “there’s been a lot of hype” about the risks and they are “rare, but…there” are especially egregious, given the nature of the risks to patients from GLP-1 treatment, including pancreatitis, which has led to serious complications, such as organ failure and death. According to the WARNINGS AND PRECAUTIONS, Acute Pancreatitis, section of the Wegovy PI, “acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide.” Moreover, the “gallbladder complications” documented in clinical trials for Wegovy, Ozempic, and Victoza also led to serious complications in some patients and required hospitalization or cholecystectomy (gallbladder removal).\nAdditional statements in the video, with respect to the common adverse reactions for Wegovy, Ozempic, and Victoza, are similarly misleading since they suggest that Wegovy, Ozempic, and Victoza are safer because the adverse events are less common and less severe than have been demonstrated. For example, when asked to respond to the concerns of a guest patient that experienced side effects from using GLP-1s and subsequently had to discontinue treatment, the following conversation occurs (emphasis added):\n• Ms. Winfrey: (after speaking to the guest patient “Rolanda” about her need to discontinue treatment with a GLP-1 medication due to side effects such as becoming “very nauseous” and vomiting blood) “So Dr. Velazquez, what do you have to say about that?” (36:37)\n• Dr. Velazquez: “Yeah, I think that’s about education of the side effects. It’s about effective management of the side effects.” (36:42)\n• Ms. Winfrey: “But they do have side effects?” (36:46)\n• Dr. Velazquez: “I think that they’ve gotten overhyped. Medicines have side effects, but the important part is that they’re mild to moderate in the research studies.” (36:48)\n• Dr. Butsch: “Yeah.” while nodding affirmatively in response to Dr. Velazquez (36:53)\nThese statements further compound the misleading minimization of the risks for Wegovy, Ozempic, and Victoza (particularly the common adverse events), by suggesting such risks are “overhyped.” The use of phrases such as “a lot of hype” and “overhyped” when referring to risk information misleadingly undermines the risk’s importance and severity.14 These statements also minimize the risks by describing them as “mild to moderate,” when this has not been demonstrated. Similar to the guest patient who was the subject of the above conversation, a number of patients in clinical trials taking GLP-1s, such as Wegovy, Ozempic, and Victoza, experienced adverse events, some of which were so severe that patients discontinued use of the drug. For example, according to the ADVERSE REACTIONS, Gastrointestinal Adverse Reactions section of the Wegovy PI (in pertinent part, emphasis added):\nIn clinical trials in adults, 73% of WEGOVY-treated patients and 47% of patients receiving placebo reported gastrointestinal adverse reactions, including severe reactions that were reported more frequently among patients receiving WEGOVY (4.1%) than placebo (0.9%). The most frequently reported reactions were nausea (44% vs. 16%), vomiting (25% vs. 6%) and diarrhea (30% vs. 16%).\n. . . .\nIn the pediatric clinical trial, 62% of WEGOVY-treated patients and 42% of placebotreated patients reported gastrointestinal disorders. The most frequently reported reactions were nausea (42% vs. 18%), vomiting (36% vs. 10%), and diarrhea (22% vs. 19%). Other gastrointestinal-related reactions that occurred at a higher incidence than placebo among WEGOVY-treated patients included abdominal pain, constipation, eructation, gastroesophageal reflux disease, and flatulence.\n. . . .\nPermanent discontinuation of treatment as a result of a gastrointestinal adverse reaction occurred in 4.3% of WEGOVY-treated adult patients versus 0.7% of placebo-treated patients.\nIn addition, according to the ADVERSE REACTIONS, Gastrointestinal Adverse Reactions section of the Ozempic PI (in pertinent part, emphasis added):\nIn the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving OZEMPIC than placebo (placebo 15.3%, OZEMPIC 0.5 mg 32.7%, OZEMPIC 1 mg 36.4%). The majority of reports of nausea, vomiting, and\u002For diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%).\nSimilarly, according to the ADVERSE REACTIONS, Gastrointestinal Adverse Reactions section of the Victoza PI (in pertinent part, emphasis added):\nIn the pool of 5 glycemic control, placebo-controlled adult clinical trials, withdrawals due to gastrointestinal adverse reactions, occurred in 4.3% of VICTOZA-treated patients and 0.5% of placebo-treated patients. Withdrawal due to gastrointestinal adverse events mainly occurred during the first 2-3 months of the trials.\nMoreover, the statement that “medicines have side effects,” coupled with the statement that GLP-1 side effects are “mild to moderate,” further downplays the serious nature of the risks associated with GLP-1s, like Wegovy, Ozempic, and Victoza, by suggesting that because all drugs generally have side effects, that the individual risks of GLP-1s are no more than other drugs and are therefore of little concern. There are several additional common adverse reactions, some of which were severe in nature (i.e., hypoglycemia), that were observed with Wegovy, Ozempic, and Victoza; but, as noted above, were omitted entirely from the video. Therefore, it is misleading to represent that the side effects of GLP-1s, like Wegovy, Ozempic, and Victoza, are generally “mild to moderate.”\nThe video not only omits several serious and significant risks; it also understates the minimal safety information that is disclosed, thus misrepresenting the safety profile of these drugs. By suggesting that safety or tolerability issues are “overhyped,” and by implying that these products are not associated with the serious and significant risks outlined above, the video misrepresents the safety profile of Wegovy, Ozempic, and Victoza. This implication is false or misleading and raises significant public health and safety concerns.\nFinally, the video is misleading because it fails to present information related to the side effects and contraindications for Wegovy, Ozempic, and Victoza with a prominence and readability reasonably comparable with the presentation of information relating to the benefits of Wegovy, Ozempic, and Victoza. As noted, the video contains numerous representations and suggestions about the benefits of Wegovy, Ozempic, and Victoza, while the risk information is relegated to the end of the video and briefly discussed. Of the 42-minute video, only four minutes in total are devoted to the important shared risks associated with GLP-1s, like Wegovy, Ozempic, and Victoza. Additionally, the video does not provide any signal to alert the viewer where they may be able to find additional risk information about the drugs. The overall effect of disclosing risk information in this limited manner undermines the communication of risk information and thereby misleadingly minimizes the risks associated with the use of Wegovy, Ozempic, and Victoza.\nFailure to Submit Under Form FDA-2253\nFDA regulations require any labeling or advertising devised for promotion of the drug product to be submitted at the time of initial dissemination of the labeling and at the time of initial publication of the advertisement for a prescription drug product. Each submission is required to be accompanied by a completed transmittal Form FDA-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) and is required to include a copy of the product’s current professional labeling. A copy of the video was not submitted to FDA under cover of Form FDA-2253 at the time of initial publication as required by 21 CFR 314.81(b)(3)(i).\nConclusion and Requested Action\nFor the reasons discussed above, the video misbrands Wegovy, Ozempic, and Victoza and makes the distribution of the drug in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1 (e)(5). In addition, these materials were not submitted at the time of initial dissemination or publication as required by 21 CFR 314.81(b)(3)(i).\nThis letter notifies you of our concerns and provides you with an opportunity to address them. You should take immediate action to address any violations (including, for example, ceasing and desisting promotional communications that are misleading as described above). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction. Please submit a written response to this letter within 15 working days from the date of receipt, addressing the concerns described in this letter, listing all other promotional communications (with the 2253 submission date) for Wegovy, Ozempic, and Victoza that contain representations such as those described above, and explaining your plan for discontinuation of such communications, or for ceasing distribution of Wegovy, Ozempic, and Victoza.\nIf you believe that your products are not in violation of the FD&C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\nAdditionally, we request that your submission include a comprehensive plan of action to disseminate truthful, non-misleading, and complete corrective communication(s) about the concern(s) discussed in this letter. The corrective communication(s) should be disseminated to the audience(s) that received the promotional communication(s) identified in the opening paragraph of this letter. We recommend that corrective communication(s) include a description of the promotional communication(s) identified in this letter, which misbrand Wegovy, Ozempic, and Victoza; include a summary of the concern(s) described in this letter; and provide information to correct each of these concern(s). Corrective communication(s) should be free of promotional claims and presentations. To the extent possible, corrective communication(s) should be distributed using the same media, and generally for the same duration of time and with the same frequency as the promotional communication(s) identified in the opening paragraph of this letter.\nThe concerns discussed in this letter do not necessarily constitute an exhaustive list of potential violations. It is your responsibility to ensure compliance with each applicable requirement of the FD&C Act and FDA implementing regulations.\nPlease direct your response to the Food and Drug Administration, Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-B Ammendale Road, Beltsville, Maryland 20705-1266. A courtesy copy can be sent by facsimile to (301) 847-8444. Please refer to MA 774, MA 1352, and MA 2028 in addition to the NDA numbers in all future correspondence relating to this particular matter. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. You are encouraged, but not required, to submit your response in eCTD format. All correspondence submitted in response to this letter should be placed under eCTD Heading 1.15.1.6. Questions related to the submission of your response letter should be emailed to CDEROPDP-RPM@fda.hhs.gov.\n\nSincerely,\n{See appended electronic signature page}\nGeorge Tidmarsh, M.D., Ph.D.\nDirector\nCenter for Drug Evaluation and Research\n--------------------------------------------------------------------------------------------\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n--------------------------------------------------------------------------------------------\n\u002Fs\u002F\n------------------------------------------------------------\nCARTER M BEACH\n09\u002F09\u002F2025 05:18:24 PM\nOn behalf of George Tidmarsh, M.D., Ph.D\nPromotional Material\n\n1Dr. W. Scott Butsch is a health care provider who serves as the Director of Obesity Medicine at the Bariatric\nInstitute of Cleveland Clinic. Dr. Butsch has financial and consultancy connections to Novo Nordisk. Based on\ncurrently available data, from 2017-2023, the Centers for Medicare and Medicaid Services Open Payments Data\nwebsite reports that Dr. Butsch has received (b)(4) in consulting fees, grants, and other payments from\nNovo Nordisk (https:\u002F\u002Fopenpaymentsdata.cms.gov\u002Fphysician\u002F1050529).\n\n2Dr. Amanda Velazquez is a health care provider who serves as the Director of Obesity Medicine at Cedars-\nSinai Medical Center. Dr. Velazquez has financial and consultancy connections to Novo Nordisk. Based on\ncurrently available data, from 2019-2023, the Centers for Medicare and Medicaid Services Open Payments Data\nwebsite reports that Dr. Velazquez has received (b)(4) in consulting fees, grants, and other payments\nfrom Novo Nordisk (https:\u002F\u002Fopenpaymentsdata.cms.gov\u002Fphysician\u002F439627).\n\n3GLP-1 = Glucagon-like Peptide-1\n\n4At approximately 20 minutes and 46 seconds, the video includes the following prominent on-screen text: “Dr.\nButsch and Dr. Velazquez consult for and receive research funding from companies making GLP-1 drugs.”\n\n5Negelle Morris is Senior Vice President, Novo Nordisk Inc. (NNI) Cardiometabolic Sales.\nhttps:\u002F\u002Fwww.novonordisk-us.com\u002Fabout\u002Four-executive-team\u002Fnegelle-morris.html\n\n6This video is available on the internet at https:\u002F\u002Fabc.com\u002Fshows\u002Fan-oprah-special-shame-blame-and-theweight-\nloss-revolution\u002Fepisode-guide\u002Fseason-01\u002F01-an-oprah-special-shame-blame-and-the-weight-lossrevolution\n(last accessed date September 8, 2025)\n\n7This information is for background purposes only and does not necessarily represent the risk information that\nshould be included in the promotional communication(s) cited in this letter.\n\n8The version of the Wegovy PI referred to in this letter is dated March 2024.\n\n9The version of the Ozempic PI referred to in this letter is dated September 2023.\n\n10The version of the Victoza PI referred to in this letter is dated July 2023.\n\n11The entirety of this video is focused on weight loss and weight loss products, specifically GLP-1s. While\ndiabetes is briefly mentioned, the majority of the program focuses on weight loss. Ozempic and Victoza are not\nFDA-approved for weight loss.\n\n12See supra footnotes 1, 2, and 3.\n\n13We note that shortly after the segment on side effects, Ms. Morris was introduced (38:19) as Vice President of\nSales for Novo Nordisk. Although Ms. Morris appeared to be present during the filming of the side effects\nsegment video, Ms. Morris made no additions to the limited risk presentation or interjected any corrections to the\nmisleading representations made by the previous representatives of Novo Nordisk.\n\n14While these and other statements made by Dr. Velazquez may be a reflection of their experience as a health\ncare provider treating patients with GLP-1s, like Wegovy, Ozempic and Victoza, their personal experience does\nnot support the representation in a promotional communication regarding the benefits of these drugs that the\nserious risks associated with Wegovy, Ozempic, and Victoza have received “a lot of hype” or have been\n“overhyped.”","novo-nordisk-inc-716495-09092025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnovo-nordisk-inc-716495-09092025","2026-10-26T08:09:35.307621+00:00","2025-09-16","716495","Maziar Mike Doustdar","2026-08-19T16:23:55.791+00:00","2025-09-09",{"id":74,"raw":75,"subject":80,"body_html":81,"body_text":82,"firm_name":83,"letter_id":84,"created_at":85,"fei_number":19,"letter_url":86,"updated_at":87,"action_type":22,"case_status":23,"posted_date":88,"marcs_cms_no":89,"product_type":26,"closeout_date":19,"issuing_office":79,"recipient_name":90,"body_fetched_at":91,"delivery_method":92,"recipient_title":19,"reference_number":19,"action_taken_date":93,"medical_device_id":19,"response_letter_date":19},3497,[76,77,78,79,80,13,13,13],"\u003Ctime datetime=\"2021-03-02T14:20:00Z\">03\u002F02\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-02-25T05:00:00Z\">02\u002F25\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finovaker-lab-sa-de-cv-609979-02252021\">Inovaker Lab S.A. de C.V.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Victor Manuel Escarcega Gomez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Inovaker Lab S.A. de C.V.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Luis Quintanar Poniente 1105 Bella Vista\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>64410\u003C\u002Fspan> \u003Cspan>Monterrey\u003C\u002Fspan>, \u003Cspan>N.L.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mexico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-21-29\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nFebruary 25, 2021\u003Cbr>\n\u003Cbr>\nDear Mr. Gomez:\u003C\u002Fp>\n\n\u003Cp>Your firm recently registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a topical antiseptic drug product labeled as Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution. This drug product was labeled as and declared to be manufactured at your facility, Inovaker Lab S.A. de C.V., FEI 3009028673 at Luis Quintanar Poniente 1105 Bella Vista, Monterrey, Nuevo Leon. Following an attempt to import Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution into the United States, it was detained and refused admission at the border.\u003C\u002Fp>\n\n\u003Cp>The results of the FDA laboratory testing of a batch of the product detained at the border demonstrate that the Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution drug product, labeled as and declared to be manufactured at your facility, is adulterated within the meaning of section 501(c) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act or Act), 21 U.S.C. 351(c), in that its strength, purity, or quality falls below that which it purports or is represented to possess. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B)), in that the subpotency demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\u003C\u002Fp>\n\n\u003Cp>In addition, Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and misbranded under sections 502(a) and (ee) of the FD&amp;C Act, 21 U.S.C. 352(a) and (ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution, labeled as and declared to be manufactured at your facility, is labeled to contain 75% volume\u002Fvolume (v\u002Fv) of the active ingredient ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained no ethanol or 0% v\u002Fv. This topical antiseptic drug product is adulterated under section 501(c) of the Act in that the active ingredient of ethanol is not present and this product does not contain the active ingredient declared on its labeling.\u003C\u002Fp>\n\n\u003Cp>CDC recommends\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> that, if soap and water are not readily available, consumers use an alcohol-based hand sanitizer that contains not less than 60% alcohol (ethanol). This is the minimum active ingredient concentration of ethanol specified in the 1994 Tentative Final Monograph for Health-Care Antiseptic Drug Products (59 FR 31402), as further amended by the “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016). The observed lack of active ingredient in your product is of particular concern because this product is labeled for use as a “health care personnel hand rub”.\u003C\u002Fp>\n\n\u003Cp>On September 23, 2020, FDA held a teleconference with you and your registered U.S. Agent, Fiesta Union LLC. We recommended you consider initiating a recall of all hand sanitizer drug products currently in distribution in the U.S. market. However, as of the date of this letter you have yet to initiate a recall. On October 13, 2020, you informed FDA that you did not recognize this import and believed your business identity was being used by another party.\u003C\u002Fp>\n\n\u003Cp>On September 24, 2020, FDA notified the public of the subpotency of your topical antiseptic drug products at the following website: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>In response to this letter provide the following:\u003C\u002Fp>\n\n\u003Cp>• A detailed investigation into how the drug product described above, which was labeled as and declared to be manufactured at your facility, and which was labeled as containing 75% v\u002Fv ethanol, in fact contained 0% ethanol.\u003C\u002Fp>\n\n\u003Cp>• A list of all raw materials used to manufacture your topical antiseptic drug products, including the suppliers’ names, addresses, and contact information.\u003C\u002Fp>\n\n\u003Cp>• A list of all batches of any topical antiseptic drug products (including products labeled as containing ethanol or isopropanol (isopropyl alcohol) as the active ingredient) shipped to the United States, and a full reconciliation of all material you distributed.\u003C\u002Fp>\n\n\u003Cp>• Copies of the complete batch records for all topical antiseptic drug product batches (including products with ethanol or isopropyl alcohol as the active ingredient) distributed to the U.S.\u003C\u002Fp>\n\n\u003Cp>• During the teleconference with FDA on September 23, 2020, you stated that your topical antiseptic drug product batches are tested and must meet specifications prior to release.\u003C\u002Fp>\n\n\u003Cp>o Provide the tests, test methods, and specifications for Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution and all other topical antiseptic products that have been imported into the US, including products labeled as isopropyl alcohol based hand sanitizers. State which tests are performed by your facility. If any testing is performed by contract laboratories, provide the name of the outside laboratories, their address, and the testing they perform.\u003Cbr>\no Provide the drug product release testing results for all batches of topical antiseptic drug products (including products labeled as ethanol or isopropyl alcohol based hand sanitizers) imported into the US or offered for import, including the batches in entry \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;submitted for import on \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>The subpotency of topical antiseptic drug product labeled as and declared to be manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&amp;C Act.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution is intended for use as a topical antiseptic.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution product label that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“Hand Sanitizer . . . Drug Facts . . . Purpose Antiseptic . . . Use(s) Health care personnel hand rub to help reduce bacteria that potentially can cause disease.”\u003C\u002Fp>\n\n\u003Cp>“Direction. . .Place enough product on hands to cover all surfaces. Rub hands together until dry.”\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>This topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product, as further described below) or under other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under FDA’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the- Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Health Care Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; and Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 80 FR 25166 (May 1, 2015) (Health Care Antiseptics Proposed Rule) and “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic Rubs Proposed Rule).\u003C\u002Fp>\n\n\u003Cp>Over the course of these rulemakings, benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol were classified as Category III for use as active ingredients in consumer antiseptic rub products and health care personnel hand rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub or as a health care personnel hand rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 -- and that were not classified as Category II for safety or effectiveness -- are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution does not conform to the 1994 TFM, as further amended by the 2015 Health Care Antiseptics Proposed Rule, the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>According to the product label, Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution purportedly contains the active ingredient ethanol 75% v\u002Fv. However, as previously discussed, FDA laboratory analyses of a batch of this product detained at the border demonstrate that Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution contains no traceable amount of ethanol.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Such a product does not conform to the TFM or the other applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers and health care personnel hand rubs during the COVID-19 public health emergency.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Additionally, this topical antiseptic, Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution, is misbranded under sections 502(a) and (ee) of the FD&amp;C Act, 21 U.S.C. 352(a) and (ee).\u003C\u002Fp>\n\n\u003Cp>The drug product is misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a), because its labeling is false or misleading. As noted above, Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution is labeled to contain ethanol 75% v\u002Fv. However, FDA laboratory analyses of a batch of this product demonstrate that the product contains no traceable amount of ethanol, far less than that stated in its product labels. Thus, the misleading representations of the concentration of the active ingredient ethanol on the Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution labeling cause the product to be misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a).\u003C\u002Fp>\n\n\u003Cp>This product is also misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution is a nonprescription drug governed by section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and it is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified, as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements, if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed drugs and drug products manufactured by your firm on Import Alert 66-78 on October 2, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as you continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\u003Cbr>\n\u003Cbr>\nPlease identify your response with FEI 3009028673 and ATTN: Christina Capacci-Daniel.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nRegistered U.S. Agent:\u003Cbr>\nAldo Martinez\u003Cbr>\nFiesta Union LLC\u003Cbr>\n34 Pinar del Rio Ave.\u003Cbr>\nBrownsville, TX 78526\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> \u003Ca href=\"https:\u002F\u002Fwww.cdc.gov\u002Fhandwashing\u002Fhand-sanitizer-use.html\">https:\u002F\u002Fwww.cdc.gov\u002Fhandwashing\u002Fhand-sanitizer-use.html\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the subpotency of the topical antiseptic product declared and labeled as manufactured at your facility, a review of the purported formulations on the drug product labeling further indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> We note that your Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution labeling contains conflicting information regarding whether it should be used as a consumer antiseptic rub or a health care personnel hand rub. The term “hand sanitizer” generally refers to consumer antiseptic rubs, and your product labeling both indicates that the product is a “hand sanitizer” and suggests that it should be used as a health care personnel hand rub (i.e., “Use(s) Health care personnel hand rub to help reduce bacteria that potentially can cause disease”). The Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution product, however, does not conform to the requirements for either a consumer antiseptic rub or a health care personnel hand rub, as further described below.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR at 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem>. Because Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution is not consistent with the formulations in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nVictor Manuel Escarcega Gomez\n\nRecipient Title\n\nCEO\n\nInovaker Lab S.A. de C.V.\n\nLuis Quintanar Poniente 1105 Bella Vista\n\n64410 Monterrey, N.L.\n\nMexico\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-21-29\n\nFebruary 25, 2021\n\nDear Mr. Gomez:\n\nYour firm recently registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a topical antiseptic drug product labeled as Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution. This drug product was labeled as and declared to be manufactured at your facility, Inovaker Lab S.A. de C.V., FEI 3009028673 at Luis Quintanar Poniente 1105 Bella Vista, Monterrey, Nuevo Leon. Following an attempt to import Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution into the United States, it was detained and refused admission at the border.\n\nThe results of the FDA laboratory testing of a batch of the product detained at the border demonstrate that the Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution drug product, labeled as and declared to be manufactured at your facility, is adulterated within the meaning of section 501(c) of the Federal Food, Drug, and Cosmetic Act (FD&C Act or Act), 21 U.S.C. 351(c), in that its strength, purity, or quality falls below that which it purports or is represented to possess. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B)), in that the subpotency demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\n\nIn addition, Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and misbranded under sections 502(a) and (ee) of the FD&C Act, 21 U.S.C. 352(a) and (ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nAdulteration Violations\n\nHand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution, labeled as and declared to be manufactured at your facility, is labeled to contain 75% volume\u002Fvolume (v\u002Fv) of the active ingredient ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained no ethanol or 0% v\u002Fv. This topical antiseptic drug product is adulterated under section 501(c) of the Act in that the active ingredient of ethanol is not present and this product does not contain the active ingredient declared on its labeling.\n\nCDC recommends1 that, if soap and water are not readily available, consumers use an alcohol-based hand sanitizer that contains not less than 60% alcohol (ethanol). This is the minimum active ingredient concentration of ethanol specified in the 1994 Tentative Final Monograph for Health-Care Antiseptic Drug Products (59 FR 31402), as further amended by the “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016). The observed lack of active ingredient in your product is of particular concern because this product is labeled for use as a “health care personnel hand rub”.\n\nOn September 23, 2020, FDA held a teleconference with you and your registered U.S. Agent, Fiesta Union LLC. We recommended you consider initiating a recall of all hand sanitizer drug products currently in distribution in the U.S. market. However, as of the date of this letter you have yet to initiate a recall. On October 13, 2020, you informed FDA that you did not recognize this import and believed your business identity was being used by another party.\n\nOn September 24, 2020, FDA notified the public of the subpotency of your topical antiseptic drug products at the following website: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\n\nIn response to this letter provide the following:\n\n• A detailed investigation into how the drug product described above, which was labeled as and declared to be manufactured at your facility, and which was labeled as containing 75% v\u002Fv ethanol, in fact contained 0% ethanol.\n\n• A list of all raw materials used to manufacture your topical antiseptic drug products, including the suppliers’ names, addresses, and contact information.\n\n• A list of all batches of any topical antiseptic drug products (including products labeled as containing ethanol or isopropanol (isopropyl alcohol) as the active ingredient) shipped to the United States, and a full reconciliation of all material you distributed.\n\n• Copies of the complete batch records for all topical antiseptic drug product batches (including products with ethanol or isopropyl alcohol as the active ingredient) distributed to the U.S.\n\n• During the teleconference with FDA on September 23, 2020, you stated that your topical antiseptic drug product batches are tested and must meet specifications prior to release.\n\no Provide the tests, test methods, and specifications for Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution and all other topical antiseptic products that have been imported into the US, including products labeled as isopropyl alcohol based hand sanitizers. State which tests are performed by your facility. If any testing is performed by contract laboratories, provide the name of the outside laboratories, their address, and the testing they perform.\n\no Provide the drug product release testing results for all batches of topical antiseptic drug products (including products labeled as ethanol or isopropyl alcohol based hand sanitizers) imported into the US or offered for import, including the batches in entry (b)(4) submitted for import on (b)(4).\n\nThe subpotency of topical antiseptic drug product labeled as and declared to be manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act.2\n\nUnapproved New Drug and Misbranding Violations\n\nHand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution is intended for use as a topical antiseptic.\n\nExamples of claims observed on the Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution product label that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\n“Hand Sanitizer . . . Drug Facts . . . Purpose Antiseptic . . . Use(s) Health care personnel hand rub to help reduce bacteria that potentially can cause disease.”\n\n“Direction. . .Place enough product on hands to cover all surfaces. Rub hands together until dry.”3\n\nThis topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product, as further described below) or under other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under FDA’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the- Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Health Care Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; and Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 80 FR 25166 (May 1, 2015) (Health Care Antiseptics Proposed Rule) and “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic Rubs Proposed Rule).\n\nOver the course of these rulemakings, benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol were classified as Category III for use as active ingredients in consumer antiseptic rub products and health care personnel hand rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub or as a health care personnel hand rub.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 -- and that were not classified as Category II for safety or effectiveness -- are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution does not conform to the 1994 TFM, as further amended by the 2015 Health Care Antiseptics Proposed Rule, the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nAccording to the product label, Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution purportedly contains the active ingredient ethanol 75% v\u002Fv. However, as previously discussed, FDA laboratory analyses of a batch of this product detained at the border demonstrate that Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution contains no traceable amount of ethanol.4 Such a product does not conform to the TFM or the other applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers and health care personnel hand rubs during the COVID-19 public health emergency.5\n\nAdditionally, this topical antiseptic, Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution, is misbranded under sections 502(a) and (ee) of the FD&C Act, 21 U.S.C. 352(a) and (ee).\n\nThe drug product is misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a), because its labeling is false or misleading. As noted above, Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution is labeled to contain ethanol 75% v\u002Fv. However, FDA laboratory analyses of a batch of this product demonstrate that the product contains no traceable amount of ethanol, far less than that stated in its product labels. Thus, the misleading representations of the concentration of the active ingredient ethanol on the Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution labeling cause the product to be misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a).\n\nThis product is also misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution is a nonprescription drug governed by section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and it is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified, as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements, if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed drugs and drug products manufactured by your firm on Import Alert 66-78 on October 2, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as you continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\n\nPlease identify your response with FEI 3009028673 and ATTN: Christina Capacci-Daniel.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC:\n\nRegistered U.S. Agent:\n\nAldo Martinez\n\nFiesta Union LLC\n\n34 Pinar del Rio Ave.\n\nBrownsville, TX 78526\n\n__________________________\n\n1 https:\u002F\u002Fwww.cdc.gov\u002Fhandwashing\u002Fhand-sanitizer-use.html\n\n2 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the subpotency of the topical antiseptic product declared and labeled as manufactured at your facility, a review of the purported formulations on the drug product labeling further indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n3 We note that your Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution labeling contains conflicting information regarding whether it should be used as a consumer antiseptic rub or a health care personnel hand rub. The term “hand sanitizer” generally refers to consumer antiseptic rubs, and your product labeling both indicates that the product is a “hand sanitizer” and suggests that it should be used as a health care personnel hand rub (i.e., “Use(s) Health care personnel hand rub to help reduce bacteria that potentially can cause disease”). The Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution product, however, does not conform to the requirements for either a consumer antiseptic rub or a health care personnel hand rub, as further described below.\n\n4 The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR at 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\n\n5 See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because Hand+ Sanitizer Ethyl Alcohol Antiseptic 75% Topical Solution is not consistent with the formulations in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.","Inovaker Lab S.A. de C.V.","inovaker-lab-sa-de-cv-609979-02252021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finovaker-lab-sa-de-cv-609979-02252021","2026-10-26T08:08:59.256598+00:00","2021-03-02","609979","Victor Manuel Escarcega Gomez","2026-08-20T03:19:53.903+00:00","VIA UPS","2021-02-25",{"id":95,"raw":96,"subject":101,"body_html":102,"body_text":103,"firm_name":104,"letter_id":105,"created_at":106,"fei_number":19,"letter_url":107,"updated_at":108,"action_type":22,"case_status":23,"posted_date":109,"marcs_cms_no":110,"product_type":111,"closeout_date":19,"issuing_office":112,"recipient_name":113,"body_fetched_at":114,"delivery_method":30,"recipient_title":19,"reference_number":19,"action_taken_date":115,"medical_device_id":19,"response_letter_date":19},2140,[97,98,99,100,101,13,13,13],"\u003Ctime datetime=\"2023-04-04T13:20:00Z\">04\u002F04\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-23T04:00:00Z\">03\u002F23\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsynovo-production-inc-647427-03232023\">Synovo Production, Inc.\u003C\u002Fa>"," Division of Medical Device and Radiological Health Operations West","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Woojoo Kim\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Synovo Production, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1501 N Harbor Blvd Ste 209\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fullerton\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92835-3803\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ceo@synovopro.com\"> ceo@synovopro.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Medical Device and Radiological Health Operations West\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER CMS # 647427\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 23, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Kim:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Synovo Production, Inc. (Synovo or “the firm”), located in Fullerton, CA, on October 11, 2022, through October 26, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer, manufacturer, and distributor of the “Femoral Resurfacing Cup,” which is distributed both as a stand-alone product and marketed as a component of the “Total Hip System.”\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Both these products are intended for a range of orthopedic procedures, including, but not limited to, hip arthroplasty and reconstruction. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease in man, or intended to affect the structure or any function of the body of man.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your firm currently holds a 510(k) clearance for the Femoral Resurfacing Cup. This device was cleared on May 23, 1991 under K904870 with the name “Modified New Jersey Femoral Hip Resurfacing Component” and was assigned product code KXA. This device was cleared, among other things, for painful hip cup arthroplasty. The clearance letter associated with this device further advised that:\u003C\u002Fp>\n\n\u003Cp>1. This device may not be labeled or promoted for non-cemented use.\u003C\u002Fp>\n\n\u003Cp>2. All labeling for this device, including package label and labeling included within the package, must prominently state that the device is intended for cemented use only.\u003C\u002Fp>\n\n\u003Cp>3. Any non-cemented fixation of this device is considered investigational and may only be investigated as a significant risk device in accordance with the investigational device exemption regulation under 21 CFR, Part 812. All users of the device for non-cemented fixation must receive approval from their respective institutional review boards and the Food and Drug Administration to conduct the investigation.\u003C\u002Fp>\n\n\u003Cp>However, since the time it was cleared, the Femoral Resurfacing Cup has been, in multiple ways, significantly changed or modified in design, components, method of manufacture, or intended use within the meaning of 21 CFR 807.81(a)(3). Specifically, significant changes to the Femoral Resurfacing Cup’s fixation have been made that include, among other things, a change to the coating specifications and associated differences in intended use. According to the instructions for use collected during the inspection, “the underside of the resurfacing component has a coating for \u003Cem>cementless fixation\u003C\u002Fem>” (emphasis added), which is contradictory to the K904870 clearance letter. The referenced changes, individually and collectively, are likely to expose patients to increased risks of loosening and subsequent revision surgery (e.g., from pain, proximal femur fracture, or component fracture).\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> These and other changes could significantly affect the safety or effectiveness of the device within the meaning of 21 CFR 807.81(a)(3). Accordingly, your firm was required to submit a new premarket notification submission under section 510(k) of the Act, 21 U.S.C. § 360(k), to FDA at least 90 days before you proposed to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the further modified Femoral Resurfacing Cup (See 21 CFR 807.81(a)(3)).\u003C\u002Fp>\n\n\u003Cp>You did not submit any new 510(k) for the referenced modifications to the Femoral Resurfacing Cup. The Femoral Resurfacing Cup, when distributed as an individual device separate from the Total Hip System, is therefore misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify FDA of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of this device, as required by section 510(k) of the Act.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that the Femoral Resurfacing Cup is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved Premarket Approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that you are also marketing the Femoral Resurfacing Cup as a component of the Total Hip System. Specifically, based on the totality of the labeling collected during inspection, the Total Hip System is intended for use as a semi-constrained total hip joint replacement device composed of an acetabular fixation cup with a polyethylene bearing surface in combination with a femoral resurfacing cup. FDA has classified this type of hip joint replacement device as class III under 21 CFR 888.3410 (product codes KXB for cemented prostheses or OCG for non-cemented prostheses). These class III device types require submission and approval of a PMA in order to obtain marketing authorization.\u003C\u002Fp>\n\n\u003Cp>The Total Hip System is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved PMA in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The Total Hip System is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\u003C\u002Fa>. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that the Total Hip System device and Femoral Resurfacing Cup are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to validate according to established procedures where results of a process cannot be fully verified by subsequent inspection and test, as required by 21 CFR 820.75(a). Specifically, you changed the biologic fixation coating for the hip replacement system from a sintered beads porous coating to a Titanium Plasma Spray (TPS) coating in April 2020. You have a Letter to File for the process change, but you could not provide evidence that a validation was performed for the change. You also discontinued the second machining process for the Femoral Resurfacing Component, but you could not provide evidence that a validation was performed for the process change. You did not follow your Process Control SOP2-007, Rev. D which states that re-validation shall be considered, and typically required, for a manufacturing process change.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a). Specifically, per a request from a surgeon in July 2022, you manufactured three units of a Femoral Resurfacing Cup Lot 01030049T to shorten the stem by 1cm. You did not follow your Design Control SOP-008, Rev. D in that you did not manage the change by documenting the design change, perform appropriate verification and validation, and keep a record of reviews.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish procedures for implementing corrective and preventive action as required by 21 CFR 820.100(a). Specifically, your firm opened Process CAR 1008 to address the issue of the TPS coating adhering poorly to the Femoral Resurfacing Component. You determined that a second machining process was causing delamination of the coating and you removed the second machining process. You received sample parts from DOT America and certificates from the supplier SynusBio for the new lot, but you could not provide evidence that the corrective action was found to be effective. You did not follow your Corrective Action and Preventive Action SOP2-014, Rev. D which states that effectivity checks should be performed at an appropriate time after the corrective action file has been closed.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50. Specifically, your firm was unable to provide a supplier assessment form for your re-packager\u002Fsterilizer BioPro, Inc. You did not follow your Supplier Qualification SOP2-028, Rev. C which states that a Supplier\u002FConsultant Form (SOP2-028-01) will be completed to document preliminary information about the supplier; that QA\u002FRA will review the information as to whether to proceed with the qualification process; and that qualification occurs before utilizing the supplier\u002Fconsultant. During the inspection, you also completed an initial supplier assessment for your supplier of raw materials, SynusBio, but had not completed it prior to utilizing the supplier.\u003C\u002Fp>\n\n\u003Cp>5. Failure to document the dates and results of quality system reviews by management with executive responsibility as required by 21 CFR 820.20(c). Specifically, your firm could not provide evidence that it conducted management reviews since its inception in April 2020. You did not follow your Management Review SOP2-011, Rev. D which states that at least once a year top management will meet to review the suitability and effectiveness of the quality system.\u003C\u002Fp>\n\n\u003Cp>6. Failure to conduct quality audits as required by 21 CFR 820.22. Specifically, your firm could not provide evidence that an annual audit had occurred in 2021. You did not follow your Internal Audit SOP2-024, Rev. D which states that each quality system element listed on the audit schedule will be audited at a minimum of once per year.\u003C\u002Fp>\n\n\u003Cp>7. Failure to document personnel training as required by 820.25(b). Specifically, your firm could not provide training records for your Regulatory Affairs (RA) Manager. You did not follow your Training and Personnel Qualification SOP2-018, Rev. D which states that a training record form (SOP-018-91) and electronic documentation of training shall be completed. The RA Manager also stated that your firm does not have training records for your firm’s other employees.\u003C\u002Fp>\n\n\u003Cp>Furthermore, under section 510 of the Act (21 U.S.C. § 360), manufacturers of medical devices are required to annually register with the FDA. In September 2007, section 510 of the Act was amended by the Food and Drug Administration Amendments Act of 2007 (Pub. L. 110-85) to require domestic and foreign device establishments to submit their annual establishment registration and device listing information to FDA by electronic means (section 510(p) of the Act, 21 U.S.C. § 360(p)), during the period beginning October 1st and ending December 31st of each year. Our inspection revealed that your firm was not currently registered with FDA as a device specification developer, manufacturer, or distributor, nor were any of the devices associated with your firm listed with FDA. You indicated to our inspector that you would complete the registration and listing process. As of the date of this letter, our records indicate that your firm has not fulfilled annual registration and listing requirements for fiscal year 2023.\u003C\u002Fp>\n\n\u003Cp>Therefore, all your firm’s devices are misbranded within the meaning of section 502(o) of the Act (21 U.S.C. § 352(0)), in that the devices were manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act (21 U.S.C. § 360) and were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\u003C\u002Fp>\n\n\u003Cp>During our inspection of your firm, you indicated that Synovo would respond in writing within fifteen business days after the completion of the inspection. As of the date of this letter, FDA has not received such response.\u003C\u002Fp>\n\n\u003Cp>Your firm should immediately cease manufacture of the Total Hip System and Femoral Resurfacing Cup with the modified underside and labeled for non-cemented use and take prompt action to correct the violations addressed in this letter. Failure to address this matter promptly and adequately may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Jessica Mu, Director of Compliance Branch at oradevices3firmresponse@fda.hhs.gov. Refer to CMS # 647427 when replying. If you have any questions about the contents of this letter, please contact: Raymond W. Brullo, Compliance Officer at 949-608-2918 or raymond.brullo@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Raquel Peat, PhD, MPH, USPHS\u003Cbr>\nDirector\u003Cbr>\nOHT 6: Office of Orthopedic Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nOperations Division 3\u002FWest\u003C\u002Fp>\n\n\u003Cp>____________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The Total Hip System is also referred to in labeling for the Femoral Resurfacing Cup as the “Synovo Hip Replacement System.” The Total Hip System is also comprised of additional components, including but not limited to the “Acetabular Fixation Cup” and “Acetabular Bearing.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Additionally, you have changed the coating specifications of the “Acetabular Fixation Cup” cleared under K963101 which also exposes patients to increased risks of loosening and subsequent revision surgery.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Woojoo Kim\n\nRecipient Title\n\nCEO\n\nSynovo Production, Inc.\n\n1501 N Harbor Blvd Ste 209\n\nFullerton, CA 92835-3803\n\nUnited States\n\nceo@synovopro.com\n\nIssuing Office:\n\nDivision of Medical Device and Radiological Health Operations West\n\nUnited States\n\nWARNING LETTER CMS # 647427\n\nMarch 23, 2023\n\nDear Mr. Kim:\n\nDuring an inspection of your firm, Synovo Production, Inc. (Synovo or “the firm”), located in Fullerton, CA, on October 11, 2022, through October 26, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer, manufacturer, and distributor of the “Femoral Resurfacing Cup,” which is distributed both as a stand-alone product and marketed as a component of the “Total Hip System.”1 Both these products are intended for a range of orthopedic procedures, including, but not limited to, hip arthroplasty and reconstruction. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease in man, or intended to affect the structure or any function of the body of man.\n\nOur inspection revealed that your firm currently holds a 510(k) clearance for the Femoral Resurfacing Cup. This device was cleared on May 23, 1991 under K904870 with the name “Modified New Jersey Femoral Hip Resurfacing Component” and was assigned product code KXA. This device was cleared, among other things, for painful hip cup arthroplasty. The clearance letter associated with this device further advised that:\n\n1. This device may not be labeled or promoted for non-cemented use.\n\n2. All labeling for this device, including package label and labeling included within the package, must prominently state that the device is intended for cemented use only.\n\n3. Any non-cemented fixation of this device is considered investigational and may only be investigated as a significant risk device in accordance with the investigational device exemption regulation under 21 CFR, Part 812. All users of the device for non-cemented fixation must receive approval from their respective institutional review boards and the Food and Drug Administration to conduct the investigation.\n\nHowever, since the time it was cleared, the Femoral Resurfacing Cup has been, in multiple ways, significantly changed or modified in design, components, method of manufacture, or intended use within the meaning of 21 CFR 807.81(a)(3). Specifically, significant changes to the Femoral Resurfacing Cup’s fixation have been made that include, among other things, a change to the coating specifications and associated differences in intended use. According to the instructions for use collected during the inspection, “the underside of the resurfacing component has a coating for cementless fixation” (emphasis added), which is contradictory to the K904870 clearance letter. The referenced changes, individually and collectively, are likely to expose patients to increased risks of loosening and subsequent revision surgery (e.g., from pain, proximal femur fracture, or component fracture).2 These and other changes could significantly affect the safety or effectiveness of the device within the meaning of 21 CFR 807.81(a)(3). Accordingly, your firm was required to submit a new premarket notification submission under section 510(k) of the Act, 21 U.S.C. § 360(k), to FDA at least 90 days before you proposed to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the further modified Femoral Resurfacing Cup (See 21 CFR 807.81(a)(3)).\n\nYou did not submit any new 510(k) for the referenced modifications to the Femoral Resurfacing Cup. The Femoral Resurfacing Cup, when distributed as an individual device separate from the Total Hip System, is therefore misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify FDA of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of this device, as required by section 510(k) of the Act.\n\nOur inspection also revealed that the Femoral Resurfacing Cup is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved Premarket Approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g).\n\nOur inspection revealed that you are also marketing the Femoral Resurfacing Cup as a component of the Total Hip System. Specifically, based on the totality of the labeling collected during inspection, the Total Hip System is intended for use as a semi-constrained total hip joint replacement device composed of an acetabular fixation cup with a polyethylene bearing surface in combination with a femoral resurfacing cup. FDA has classified this type of hip joint replacement device as class III under 21 CFR 888.3410 (product codes KXB for cemented prostheses or OCG for non-cemented prostheses). These class III device types require submission and approval of a PMA in order to obtain marketing authorization.\n\nThe Total Hip System is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved PMA in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The Total Hip System is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nOur inspection also revealed that the Total Hip System device and Femoral Resurfacing Cup are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\n\n1. Failure to validate according to established procedures where results of a process cannot be fully verified by subsequent inspection and test, as required by 21 CFR 820.75(a). Specifically, you changed the biologic fixation coating for the hip replacement system from a sintered beads porous coating to a Titanium Plasma Spray (TPS) coating in April 2020. You have a Letter to File for the process change, but you could not provide evidence that a validation was performed for the change. You also discontinued the second machining process for the Femoral Resurfacing Component, but you could not provide evidence that a validation was performed for the process change. You did not follow your Process Control SOP2-007, Rev. D which states that re-validation shall be considered, and typically required, for a manufacturing process change.\n\n2. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a). Specifically, per a request from a surgeon in July 2022, you manufactured three units of a Femoral Resurfacing Cup Lot 01030049T to shorten the stem by 1cm. You did not follow your Design Control SOP-008, Rev. D in that you did not manage the change by documenting the design change, perform appropriate verification and validation, and keep a record of reviews.\n\n3. Failure to establish procedures for implementing corrective and preventive action as required by 21 CFR 820.100(a). Specifically, your firm opened Process CAR 1008 to address the issue of the TPS coating adhering poorly to the Femoral Resurfacing Component. You determined that a second machining process was causing delamination of the coating and you removed the second machining process. You received sample parts from DOT America and certificates from the supplier SynusBio for the new lot, but you could not provide evidence that the corrective action was found to be effective. You did not follow your Corrective Action and Preventive Action SOP2-014, Rev. D which states that effectivity checks should be performed at an appropriate time after the corrective action file has been closed.\n\n4. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50. Specifically, your firm was unable to provide a supplier assessment form for your re-packager\u002Fsterilizer BioPro, Inc. You did not follow your Supplier Qualification SOP2-028, Rev. C which states that a Supplier\u002FConsultant Form (SOP2-028-01) will be completed to document preliminary information about the supplier; that QA\u002FRA will review the information as to whether to proceed with the qualification process; and that qualification occurs before utilizing the supplier\u002Fconsultant. During the inspection, you also completed an initial supplier assessment for your supplier of raw materials, SynusBio, but had not completed it prior to utilizing the supplier.\n\n5. Failure to document the dates and results of quality system reviews by management with executive responsibility as required by 21 CFR 820.20(c). Specifically, your firm could not provide evidence that it conducted management reviews since its inception in April 2020. You did not follow your Management Review SOP2-011, Rev. D which states that at least once a year top management will meet to review the suitability and effectiveness of the quality system.\n\n6. Failure to conduct quality audits as required by 21 CFR 820.22. Specifically, your firm could not provide evidence that an annual audit had occurred in 2021. You did not follow your Internal Audit SOP2-024, Rev. D which states that each quality system element listed on the audit schedule will be audited at a minimum of once per year.\n\n7. Failure to document personnel training as required by 820.25(b). Specifically, your firm could not provide training records for your Regulatory Affairs (RA) Manager. You did not follow your Training and Personnel Qualification SOP2-018, Rev. D which states that a training record form (SOP-018-91) and electronic documentation of training shall be completed. The RA Manager also stated that your firm does not have training records for your firm’s other employees.\n\nFurthermore, under section 510 of the Act (21 U.S.C. § 360), manufacturers of medical devices are required to annually register with the FDA. In September 2007, section 510 of the Act was amended by the Food and Drug Administration Amendments Act of 2007 (Pub. L. 110-85) to require domestic and foreign device establishments to submit their annual establishment registration and device listing information to FDA by electronic means (section 510(p) of the Act, 21 U.S.C. § 360(p)), during the period beginning October 1st and ending December 31st of each year. Our inspection revealed that your firm was not currently registered with FDA as a device specification developer, manufacturer, or distributor, nor were any of the devices associated with your firm listed with FDA. You indicated to our inspector that you would complete the registration and listing process. As of the date of this letter, our records indicate that your firm has not fulfilled annual registration and listing requirements for fiscal year 2023.\n\nTherefore, all your firm’s devices are misbranded within the meaning of section 502(o) of the Act (21 U.S.C. § 352(0)), in that the devices were manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act (21 U.S.C. § 360) and were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\n\nDuring our inspection of your firm, you indicated that Synovo would respond in writing within fifteen business days after the completion of the inspection. As of the date of this letter, FDA has not received such response.\n\nYour firm should immediately cease manufacture of the Total Hip System and Femoral Resurfacing Cup with the modified underside and labeled for non-cemented use and take prompt action to correct the violations addressed in this letter. Failure to address this matter promptly and adequately may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Jessica Mu, Director of Compliance Branch at oradevices3firmresponse@fda.hhs.gov. Refer to CMS # 647427 when replying. If you have any questions about the contents of this letter, please contact: Raymond W. Brullo, Compliance Officer at 949-608-2918 or raymond.brullo@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Raquel Peat, PhD, MPH, USPHS\n\nDirector\n\nOHT 6: Office of Orthopedic Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nOperations Division 3\u002FWest\n\n____________________________\n\n1 The Total Hip System is also referred to in labeling for the Femoral Resurfacing Cup as the “Synovo Hip Replacement System.” The Total Hip System is also comprised of additional components, including but not limited to the “Acetabular Fixation Cup” and “Acetabular Bearing.”\n\n2 Additionally, you have changed the coating specifications of the “Acetabular Fixation Cup” cleared under K963101 which also exposes patients to increased risks of loosening and subsequent revision surgery.","Synovo Production, Inc.","synovo-production-inc-647427-03232023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsynovo-production-inc-647427-03232023","2026-10-26T08:10:09.218108+00:00","2023-04-04","647427","Medical Devices","Division of Medical Device and Radiological Health Operations West","Mr. Woojoo Kim","2026-08-20T01:10:23.537+00:00","2023-03-23",{"id":117,"raw":118,"subject":101,"body_html":123,"body_text":124,"firm_name":125,"letter_id":126,"created_at":18,"fei_number":19,"letter_url":127,"updated_at":128,"action_type":22,"case_status":23,"posted_date":129,"marcs_cms_no":130,"product_type":111,"closeout_date":19,"issuing_office":122,"recipient_name":131,"body_fetched_at":132,"delivery_method":133,"recipient_title":19,"reference_number":19,"action_taken_date":134,"medical_device_id":19,"response_letter_date":19},1546,[119,120,121,122,101,13,13,13],"\u003Ctime datetime=\"2024-03-26T13:20:00Z\">03\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-10-13T04:00:00Z\">10\u002F13\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frenovo-inc-dba-provision-device-reprocessing-solutions-664014-10132023\">ReNovo, Inc. DBA Provision Device Reprocessing Solutions\u003C\u002Fa>","Center for Devices and Radiological Health","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Kirk M. Mansberger\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>ReNovo, Inc. DBA Provision Device Reprocessing Solutions\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>340 SW Columbia St.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bend\u003C\u002Fspan>, \u003Cspan>OR\u003C\u002Fspan> \u003Cspan>97702-1035\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# 664014\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 13, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Mansberger:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at 340 SW Columbia St., Bend, OR on May 15, 2023 through May 18, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a reprocessor and distributor of reprocessed single-use devices such as Electrosurgical Ablation Wands, Electrosurgical Ear, Nose, and Throat (ENT) Coblators, Trocars, ENT Burs, Drill Bits, and Surgical Saw Blades. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>We received a response(s) from Mary Vater, Deputy Quality Manager dated June 1, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that the following devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>ReNovo Inc \u003Cstrong>(b)(4)\u003C\u002Fstrong> Single Use Device (SUD) Model Numbers \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Ablation Electrodes;\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Ablation Electrodes;\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Ablation Electrodes;\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;Coblators;\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Bipolar Sealers;\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Bipolar Sealers;\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Trochars\u002FCannulas;\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Trochars\u002FCannulas;\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Trochars\u002FCannulas;\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Ablation Electrodes;\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Ablation Electrodes;\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Ablation Electrodes;\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Trochars\u002FCannulas;\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Trochars\u002FCannulas and\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Trochars\u002FCannulas\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm added \u003Cstrong>(b)(4)\u003C\u002Fstrong> new models of \u003Cstrong>(b)(4)\u003C\u002Fstrong> by Letter to File that were not cleared K173741. For example,\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Ablation Electrodes \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Ablation Electrodes, \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Ablation Electrodes \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>These new models (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) are \u003Cstrong>(b)(4)\u003C\u002Fstrong> versions of OEM models that were not included in K173741. The additional OEM models have smaller diameter shafts, smaller diameters lumens, and smaller tip elements than the OEM models included in K173741, and they present a more challenging scenario for cleaning and re-sterilization compared to the designs of the OEM models that were included in K173741. Your company did not evaluate how cleaning and re-sterilization of the additional OEM models with different designs could affect the performance specifications and reliability of your new \u003Cstrong>(b)(4)\u003C\u002Fstrong> models.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> These changes could significantly affect the safety or effectiveness of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices and required the submission of a new 510(k). 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\n\n\u003Cp>Your firm also added \u003Cstrong>(b)(4)\u003C\u002Fstrong> new models of \u003Cstrong>(b)(4)\u003C\u002Fstrong> by Letter to File in connection with clearance K173740. For example,\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Ablation \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Ablation \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Ablation \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>These new models (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) are \u003Cstrong>(b)(4)\u003C\u002Fstrong> versions of OEM models that were not included in K173740. These additional OEM models have smaller diameter shafts, smaller diameters lumens, smaller tip elements, and\u002For longer shafts than then OEM models included in K173740, and they present a more challenging scenario for cleaning and re-sterilization compared to the designs of the OEM models that were included in K173740. Your company did not evaluate how cleaning and re-sterilization of the additional OEM models with different designs could affect the performance specifications and reliability of your new \u003Cstrong>(b)(4)\u003C\u002Fstrong> models.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> These changes could significantly affect the safety or effectiveness of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices and required the submission of a new 510(k). 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\n\n\u003Cp>Your firm also added \u003Cstrong>(b)(4)\u003C\u002Fstrong> new models of \u003Cstrong>(b)(4)\u003C\u002Fstrong> by Letter to File in connection with clearance K172647. For example,\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Coblators \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Coblators \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Coblators \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>These new models (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) are \u003Cstrong>(b)(4)\u003C\u002Fstrong> versions of OEM models that were not included in K172647. The additional OEM models have smaller diameter shafts, smaller diameters lumens, smaller tip elements, and\u002For longer shafts than the OEM models included in K172647, and they present a more challenging scenario for cleaning and re-sterilization compared to the designs of the OEM models that were included in K172647. Your company did not evaluate how cleaning and re-sterilization of the additional OEM models with different designs could affect the performance specifications and reliability of your new \u003Cstrong>(b)(4)\u003C\u002Fstrong> models.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> These changes could significantly affect the safety or effectiveness of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices and required submission of a new 510(k). 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\n\n\u003Cp>Your firm also added \u003Cstrong>(b)(4)\u003C\u002Fstrong> new models of \u003Cstrong>(b)(4)\u003C\u002Fstrong> by Letter to File in connection with clearance K172097. For example,\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Trochars\u002FCannulas \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Trochars\u002F Cannulas \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Trochars\u002FCannulas \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>These new models (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) are \u003Cstrong>(b)(4)\u003C\u002Fstrong> versions of OEM models that were not included in K172097. The additional OEM models have smaller constructional elements, and\u002For different design features than the OEM models included in K172097, and they present a more challenging scenario for cleaning and re-sterilization compared to the designs of the OEM models that were included in K172097. Your company did not evaluate how cleaning and re-sterilization of the additional OEM models with different designs could affect the performance specifications and reliability of your new \u003Cstrong>(b)(4)\u003C\u002Fstrong> models.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> These changes could significantly affect the safety or effectiveness of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices and required the submission of a new 510(k). 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\n\n\u003Cp>Your firm also added \u003Cstrong>(b)(4)\u003C\u002Fstrong> new models of \u003Cstrong>(b)(4)\u003C\u002Fstrong> by Letter to File in connection with clearance K172093. For example,\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Trochars\u002FCannulas \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Trochars\u002FCannulas \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Trochars\u002FCannulas \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>These new models (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) are \u003Cstrong>(b)(4)\u003C\u002Fstrong> versions of OEM models that were not included in K172093. The additional OEM models have smaller constructional elements, and\u002For different design features than the OEM models included in K172093, and they present a more challenging scenario for cleaning and re-sterilization compared to the designs of the OEM models that were included in K172093. Your company did not evaluate how cleaning and re-sterilization of the additional OEM models with different designs could affect the performance specifications and reliability of your new \u003Cstrong>(b)(4)\u003C\u002Fstrong> models.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> These changes could significantly affect the safety or effectiveness of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices and required submission of a new 510(k). 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to adequately establish procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). Specifically,\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s air compressor system is used for drying and operation of process equipment for manufacturing \u003Cstrong>(b)(4)\u003C\u002Fstrong> medical devices. \u003Cstrong>(b)(4)\u003C\u002Fstrong> air particulate testing, conducted on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, found the number of particles for particle sizes between 1.0μm and 5.0μm were above the specified limit, particles above \u003Cstrong>(b)(4)\u003C\u002Fstrong> were detected, and the test failed. Your firm did not initiate a non-conforming product report to assess if this nonconformance impacted product. Your firm initiated CAPA 22-003 to investigate why the air compressor failed the testing, however, this CAPA also did not assess if product may have been impacted by the failure.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and your response to this observation appears to be adequate. Please provide a timeframe for completion of your corrective actions. A follow up inspection will be required to assure that corrections and\u002For corrective actions are adequate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to adequately establish procedures to control environmental conditions, as required by 21 CFR 820.70(c). Specifically,\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm reprocesses medical devices in a controlled environment room, and your firm’s Controlled Environment Monitoring procedure, SOP-065, Version: A7, Effective: 08\u002F10\u002F2021, requires routine monitoring of air particulate measurements. This procedure states that \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Air particulate sampling began on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, however, as of \u003Cstrong>(b)(4)\u003C\u002Fstrong> your firm has not set acceptable levels for air particulate.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and your response to this observation appears to be adequate. A follow up inspection will be required to assure that corrections and\u002For corrective actions are adequate.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Jessica Mu, Director of Compliance Branch, at ORADevices3FirmResponse@fda.hhs.gov. Refer to CMS # 664014 when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Y. Perkins, Compliance Officer at (619) 941-3763 or shaquenta.perkins@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nOperations Division 3\u002FWest\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003Cbr>\nBinita S. Ashar, MD, MBA, FACS Director\u003Cbr>\nOHT 4: Office of Surgery and Infection Control Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>____________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> \u003Cem>See\u003C\u002Fem> FDA’s Guidance for Industry and Food and Drug Administration Staff on Deciding When to Submit a 510(k) for a Change to an Existing Device available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F99812\u002Fdownload.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nKirk M. Mansberger\n\nRecipient Title\n\nPresident\n\nReNovo, Inc. DBA Provision Device Reprocessing Solutions\n\n340 SW Columbia St.\n\nBend, OR 97702-1035\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nCMS# 664014\n\nOctober 13, 2023\n\nDear Mr. Mansberger:\n\nDuring an inspection of your firm located at 340 SW Columbia St., Bend, OR on May 15, 2023 through May 18, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a reprocessor and distributor of reprocessed single-use devices such as Electrosurgical Ablation Wands, Electrosurgical Ear, Nose, and Throat (ENT) Coblators, Trocars, ENT Burs, Drill Bits, and Surgical Saw Blades. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nWe received a response(s) from Mary Vater, Deputy Quality Manager dated June 1, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations.\n\nOur inspection revealed that the following devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g):\n\nReNovo Inc (b)(4) Single Use Device (SUD) Model Numbers (b)(4) Ablation Electrodes;\n\n(b)(4) Ablation Electrodes;\n\n(b)(4) Ablation Electrodes;\n\n(b)(4) Coblators;\n\n(b)(4) Bipolar Sealers;\n\n(b)(4) Bipolar Sealers;\n\n(b)(4) Trochars\u002FCannulas;\n\n(b)(4) Trochars\u002FCannulas;\n\n(b)(4) Trochars\u002FCannulas;\n\n(b)(4) Ablation Electrodes;\n\n(b)(4) Ablation Electrodes;\n\n(b)(4) Ablation Electrodes;\n\n(b)(4) Trochars\u002FCannulas;\n\n(b)(4) Trochars\u002FCannulas and\n\n(b)(4) Trochars\u002FCannulas\n\nThe devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nSpecifically, your firm added (b)(4) new models of (b)(4) by Letter to File that were not cleared K173741. For example,\n\n(b)(4) Ablation Electrodes (b)(4)\n\n(b)(4) Ablation Electrodes, (b)(4)\n\n(b)(4) Ablation Electrodes (b)(4)\n\nThese new models ((b)(4)) are (b)(4) versions of OEM models that were not included in K173741. The additional OEM models have smaller diameter shafts, smaller diameters lumens, and smaller tip elements than the OEM models included in K173741, and they present a more challenging scenario for cleaning and re-sterilization compared to the designs of the OEM models that were included in K173741. Your company did not evaluate how cleaning and re-sterilization of the additional OEM models with different designs could affect the performance specifications and reliability of your new (b)(4) models.1 These changes could significantly affect the safety or effectiveness of the (b)(4) devices and required the submission of a new 510(k). 21 CFR 807.81(a)(3)(i).\n\nYour firm also added (b)(4) new models of (b)(4) by Letter to File in connection with clearance K173740. For example,\n\n(b)(4) Ablation (b)(4)\n\n(b)(4) Ablation (b)(4)\n\n(b)(4) Ablation (b)(4)\n\nThese new models ((b)(4)) are (b)(4) versions of OEM models that were not included in K173740. These additional OEM models have smaller diameter shafts, smaller diameters lumens, smaller tip elements, and\u002For longer shafts than then OEM models included in K173740, and they present a more challenging scenario for cleaning and re-sterilization compared to the designs of the OEM models that were included in K173740. Your company did not evaluate how cleaning and re-sterilization of the additional OEM models with different designs could affect the performance specifications and reliability of your new (b)(4) models.1 These changes could significantly affect the safety or effectiveness of the (b)(4) devices and required the submission of a new 510(k). 21 CFR 807.81(a)(3)(i).\n\nYour firm also added (b)(4) new models of (b)(4) by Letter to File in connection with clearance K172647. For example,\n\n(b)(4) Coblators (b)(4)\n\n(b)(4) Coblators (b)(4)\n\n(b)(4) Coblators (b)(4)\n\nThese new models ((b)(4)) are (b)(4) versions of OEM models that were not included in K172647. The additional OEM models have smaller diameter shafts, smaller diameters lumens, smaller tip elements, and\u002For longer shafts than the OEM models included in K172647, and they present a more challenging scenario for cleaning and re-sterilization compared to the designs of the OEM models that were included in K172647. Your company did not evaluate how cleaning and re-sterilization of the additional OEM models with different designs could affect the performance specifications and reliability of your new (b)(4) models.1 These changes could significantly affect the safety or effectiveness of the (b)(4) devices and required submission of a new 510(k). 21 CFR 807.81(a)(3)(i).\n\nYour firm also added (b)(4) new models of (b)(4) by Letter to File in connection with clearance K172097. For example,\n\n(b)(4) Trochars\u002FCannulas (b)(4)\n\n(b)(4)\n\n(b)(4) Trochars\u002F Cannulas (b)(4)\n\n(b)(4)\n\n(b)(4) Trochars\u002FCannulas (b)(4)\n\nThese new models ((b)(4)) are (b)(4) versions of OEM models that were not included in K172097. The additional OEM models have smaller constructional elements, and\u002For different design features than the OEM models included in K172097, and they present a more challenging scenario for cleaning and re-sterilization compared to the designs of the OEM models that were included in K172097. Your company did not evaluate how cleaning and re-sterilization of the additional OEM models with different designs could affect the performance specifications and reliability of your new (b)(4) models.1 These changes could significantly affect the safety or effectiveness of the (b)(4) devices and required the submission of a new 510(k). 21 CFR 807.81(a)(3)(i).\n\nYour firm also added (b)(4) new models of (b)(4) by Letter to File in connection with clearance K172093. For example,\n\n(b)(4) Trochars\u002FCannulas (b)(4)\n\n(b)(4) Trochars\u002FCannulas (b)(4)\n\n(b)(4) Trochars\u002FCannulas (b)(4)\n\nThese new models ((b)(4)) are (b)(4) versions of OEM models that were not included in K172093. The additional OEM models have smaller constructional elements, and\u002For different design features than the OEM models included in K172093, and they present a more challenging scenario for cleaning and re-sterilization compared to the designs of the OEM models that were included in K172093. Your company did not evaluate how cleaning and re-sterilization of the additional OEM models with different designs could affect the performance specifications and reliability of your new (b)(4) models.1 These changes could significantly affect the safety or effectiveness of the (b)(4) devices and required submission of a new 510(k). 21 CFR 807.81(a)(3)(i).\n\nOur inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nThese violations include, but are not limited to, the following:\n\n1. Failure to adequately establish procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). Specifically,\n\nYour firm’s air compressor system is used for drying and operation of process equipment for manufacturing (b)(4) medical devices. (b)(4) air particulate testing, conducted on (b)(4), found the number of particles for particle sizes between 1.0μm and 5.0μm were above the specified limit, particles above (b)(4) were detected, and the test failed. Your firm did not initiate a non-conforming product report to assess if this nonconformance impacted product. Your firm initiated CAPA 22-003 to investigate why the air compressor failed the testing, however, this CAPA also did not assess if product may have been impacted by the failure.\n\nWe reviewed your firm’s response and your response to this observation appears to be adequate. Please provide a timeframe for completion of your corrective actions. A follow up inspection will be required to assure that corrections and\u002For corrective actions are adequate.\n\n2. Failure to adequately establish procedures to control environmental conditions, as required by 21 CFR 820.70(c). Specifically,\n\nYour firm reprocesses medical devices in a controlled environment room, and your firm’s Controlled Environment Monitoring procedure, SOP-065, Version: A7, Effective: 08\u002F10\u002F2021, requires routine monitoring of air particulate measurements. This procedure states that (b)(4). Air particulate sampling began on (b)(4), however, as of (b)(4) your firm has not set acceptable levels for air particulate.\n\nWe reviewed your firm’s response and your response to this observation appears to be adequate. A follow up inspection will be required to assure that corrections and\u002For corrective actions are adequate.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Jessica Mu, Director of Compliance Branch, at ORADevices3FirmResponse@fda.hhs.gov. Refer to CMS # 664014 when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Y. Perkins, Compliance Officer at (619) 941-3763 or shaquenta.perkins@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nOperations Division 3\u002FWest\n\n\u002FS\u002F\n\nBinita S. Ashar, MD, MBA, FACS Director\n\nOHT 4: Office of Surgery and Infection Control Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n____________________________\n\n1 See FDA’s Guidance for Industry and Food and Drug Administration Staff on Deciding When to Submit a 510(k) for a Change to an Existing Device available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F99812\u002Fdownload.","ReNovo, Inc. DBA Provision Device Reprocessing Solutions","renovo-inc-dba-provision-device-reprocessing-solutions-664014-10132023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frenovo-inc-dba-provision-device-reprocessing-solutions-664014-10132023","2026-10-26T08:09:48.74426+00:00","2024-03-26","664014","Kirk M. Mansberger","2026-08-20T00:13:25.069+00:00","VIA UNITED PARCEL SERVICE","2023-10-13",6,{"510k":137,"classification":138,"enforcement":139,"event":140,"event_backfill":141,"pma":142,"warning_letter":143},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-19T04:00:36.695+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]